paroxetine has been researched along with Depression in 337 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 43 (12.76) | 18.2507 |
2000's | 161 (47.77) | 29.6817 |
2010's | 114 (33.83) | 24.3611 |
2020's | 19 (5.64) | 2.80 |
Authors | Studies |
---|---|
Cui, P; Hao, L; He, X; Jia, Y; Liang, Z; Tong, B; Yang, F; Yuan, J; Zhao, L; Zhu, R | 1 |
Diao, Y; Dong, J; Fu, Y; Geng, M; Gu, J; Liu, C; Liu, X; Mu, J; Wang, C; Wang, H | 1 |
Fang, M; Feng, Y; Liu, S; Mayes, TL; Wang, G; Xiao, L; Zhou, J | 1 |
Bykov, K; Gagne, JJ; Yoshida, K; Yunusa, I | 1 |
Gong, A; Wu, Z; Zeng, M | 1 |
Ikenouchi, A; Okamoto, N; Yoshimura, R | 1 |
Chen, H; Cui, Z; Gao, Z; Hong, J; Li, X; Ma, Y; Ning, L; Tong, T; Wang, X; Wang, Z; Xuan, B; Yan, Y | 1 |
Chen, M; Fan, J; Guo, C; Liu, W; Liu, Y; Lu, H; Xu, J; Yang, J; Zhang, H | 1 |
Cao, Q; Rao, Y; Yang, R; Zhao, J | 1 |
Chen, YM; Guan, W; Huang, J; Jiang, B; Li, WY; Shi, TS; Xu, DW | 1 |
Bressolle-Gomeni, F; Fava, M; Gomeni, R | 1 |
Chen, ML; Gou, L; Jiang, DQ; Jiang, LL; Mo, Y; Wang, Y; Wu, YL; Zang, QM | 1 |
Konstantinou, G; Mylona, S; Paschalakis, G; Stavrinou, A; Vasilopoulou, P | 1 |
Appeldoorn, JTY; Mulder, H; Risselada, AJ; Ruhé, EG; Schene, AH; Simoons, M; van Roon, EN; van Schaik, RHN | 1 |
Garabadu, D; Krishnamurthy, S; Prajapati, SK; Singh, N | 1 |
Červeňová, J | 1 |
Han, L; Han, Z; Li, L; Yan, B | 1 |
Bates, DW; Buckeridge, DL; Dixon, WG; Girard, N; Haas, JS; Habib, B; Iqbal, U; Li, J; Sheppard, T; Tamblyn, R | 1 |
Airaksinen, J; Elovainio, M; García Velázquez, R; Gluschkoff, K; Jokela, M; Komulainen, K; Savelieva, K | 1 |
Adams, A; Baethge, C; Braun, C; Bschor, T; Kuhr, K; Rink, L | 1 |
Bambico, FR; Blundell, J; Conway, JD; Dinesh, OC; Hasan, SN; Nobrega, JN; Raymond, R; Waye, SC | 1 |
Aksoy, S; Atıcı, M; Erdogan, MS; Ertaş, ET; Isa Kara, M; Kelebek, S; Ozen, E | 1 |
Campbell Burton, CA; Chun, HY; Gillespie, D; Holmes, J; Knapp, P; Lewis, SR; Lightbody, CE; Murray, J; Watkins, CL | 1 |
Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C | 1 |
Chen, XF; Gao, NN; Jin, ZL; Li, XR; Li, YF; Ran, YH; Xiong, J; Zheng, YY | 1 |
Agius, M; Ripullone, K; Womersley, K | 1 |
Farooq, AD; Naqvi, S; Rahman, R; Zeb, F | 1 |
Chen, CY; Ho, PS; Huang, CC; Huang, SY; Kuo, SC; Liang, CS; Lu, RB; Shyu, JF; Yeh, YW; Yen, CH | 1 |
Frokjaer, VG; Galea, LAM; Lieblich, SE; Overgaard, A; Richardson, R | 1 |
He, JC; Pu, ZP; Xia, JM; Xie, W | 1 |
Beyer, JL; Johnson, KG | 1 |
Cizmarikova, M; Dragasek, J; Kolarcik, P; Mojzis, J; Vancova, Z; Zofcakova, S | 1 |
Dong, ZQ; Kuang, WH; Li, J; Tian, LT | 1 |
Li, P; Ma, C | 1 |
Cai, H; Gong, X; Guo, Y; Han, W; Jiang, P; Liao, D; Liu, M | 1 |
Boudreau, DM; Crane, PK; Edwards, KL; Fullerton, SM; Gray, SL; Heath, L; Larson, EB; Thummel, K | 1 |
Bleau, P; Hedeker, H; Moskowitz, DS; Pinard, G; Rappaport, LM; Russell, JJ | 1 |
Carson-Chahhoud, KV; Pollok, J; van Agteren, JE | 1 |
Bassi, M; Cauli, G; Gala, C; Iapichino, E; Marconi, AM; Quartieri Bollani, M; Rucci, P | 1 |
Clinton, SM; Glover, ME; Jackson, NL; McCoy, CR; Shupe, EA; Unroe, KA | 1 |
Cossu, AE; Hardacker, DM; Jea, AH; Latham, LB | 1 |
Gong, L; Yin, Y; Yue, L; Zhang, X | 1 |
Callegari, C; Caselli, I; Diurni, M; Ielmini, M; Isella, C; Lucca, G; Pettenon, F; Poloni, N | 1 |
Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S | 1 |
Eriksson, E; Hieronymus, F; Lisinski, A; Nilsson, S | 1 |
Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E | 1 |
Casarotto, PC; Guimarães, FS; Hiroaki-Sato, VA; Joca, SR; Pereira, VS; Sartim, AG | 1 |
Juřica, J; Žourková, A | 1 |
Amsterdam, JD; DeRubeis, RJ; Fournier, JC; Gallop, R; Hollon, SD; Shelton, RC | 1 |
Berk, M; Dodd, S; Kelin, K; Mancini, M; Schacht, A | 1 |
Bhatt, S; Devadoss, T; Jindal, A; Mahesh, R | 1 |
Hong, L; Lin, YN; Lu, XY; Ng, SM; Wang, F; Wang, WD; Zhao, Y | 1 |
Hou, XJ; Wang, J; Xu, JH; Yu, YY | 1 |
Achacoso, N; Friedman, GD; Habel, LA; Kroenke, CH; Meng, MV; Schwalbe, J | 1 |
Montgomery, SA; Reines, EH; Sanchez, C | 1 |
Dienel, A; Gastpar, M; Kasper, S; Möller, HJ; Müller, WE; Schläfke, S; Volz, HP | 1 |
Auinger, P; Christine, CW; Factor, SA; Juncos, J; Leentjens, AF; Lyness, JM; Marsh, L; McDonald, W; Moonen, AJ; Panisset, M; Pfeiffer, R; Richard, IH; Rottenberg, D; Serrano Ramos, C; Shulman, L; Singer, C; Slevin, J; Wijers, A | 1 |
Barbui, C; Cipriani, A; Furukawa, TA; Gastaldon, C; Magni, LR; Papola, D; Purgato, M; Rizzo, C; Trespidi, C; Watanabe, N | 1 |
Bennett, KL; Berger, J; Ghafari, M; Kotlowski, C; Kotlowsky, C; Lubec, G; Miklósi, AG; Schmuckermair, C; Singewald, N; Whittle, N | 1 |
Hu, MY; Jia, LL; Li, F; Liu, C; Liu, L; Liu, XD; Xu, D; Yang, Y; Zhang, M; Zhong, ZY | 1 |
Amsterdam, J; DeRubeis, RJ; Fournier, JC; Hollon, SD; Shelton, RC | 1 |
Baltes, BB; Grekin, ER; Kirsch, I; Loree, AM; Sugarman, MA | 1 |
Fukunaga, K; Han, F; Izumi, H; Moriguchi, S; Sakagami, H; Sasaki, Y; Yabuki, Y; Zhang, C | 1 |
Balsevich, G; Dedic, N; Deussing, JM; Eder, M; Gassen, NC; Hafner, K; Hartmann, J; Holsboer, F; Ising, M; Kirmeier, T; Kloiber, S; Kollmannsberger, L; Lucae, S; Rein, T; Schmidt, MV; Stepan, J; Uhr, M; Wagner, KV; Zellner, A; Zschocke, J | 1 |
Bétry, C; Bundgaard, C; Haddjeri, N; Mørk, A; Overstreet, D; Pehrson, AL; Sanchez, C | 1 |
Gassen, NC; Hartmann, J; Rein, T; Schmidt, MV | 1 |
De Gobbi, JI; Matsubara, BB; Matsubara, LS; Omoto, AC; Roscani, MG; Siqueira, TF | 1 |
Blanco, C; Cohen, JN; Drabick, DA; Heimberg, RG; Liebowitz, MR; Potter, CM; Schneier, FR | 1 |
Dong, C; Hashimoto, K; Hirota, S; Inanaga, K; Yao, W; Zhang, JC; Zhuang, C | 1 |
Barahona-Corrêa, B; Lampreia, T; Leitão, C; Mendonça, MD | 1 |
Files, JA; Jenkins, MR; Kransdorf, LN; McNeil, MA | 1 |
Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A | 1 |
Binder, EB; Carell, T; Carrillo-Roa, T; Chrousos, GP; Fries, GR; Gassen, NC; Hafner, K; Hartmann, J; Hoeijmakers, L; Ising, M; Kloiber, S; Knop, M; Lucae, S; Preißinger, SN; Rein, T; Rüegg, J; Schmidt, MV; Steinbacher, J; Weber, F; Zannas, AS; Zschocke, J | 1 |
Ali, J; Baboota, S; Gupta, BK; Kumar, S; Pandey, YR | 1 |
Ahmed, SA; Avila, C; Cheetham, TC; Chung, J; Fletcher, SW; Habel, LA; Haque, R; Kleinman, K; Kwan, ML; Schottinger, JE; Shi, J | 1 |
Baker, H | 1 |
Broen, MP; Köhler, S; Kuijf, ML; Leentjens, AF; McDonald, WM; Richard, IH | 1 |
Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K | 1 |
Ramzy, EA | 1 |
Bagmetova, VV; Chernysheva, YV; Ozerov, AA; Tyurenkov, IN | 1 |
Brüning, CA; Duarte, T; Mantovani, AC; Nogueira, CW; Pesarico, AP; Sartori, G; Zeni, G | 1 |
Altamura, AC; Buoli, M; Ciappolino, V; Serati, M | 1 |
Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ | 1 |
Huang, S; Liu, C; Liu, X; Ye, Y | 1 |
Chen, DY; Gu, X; Jia, L; Jiang, SM; Xie, HL; Xu, J | 1 |
Aparasu, RR; Bali, V; Carnahan, RM; Chatterjee, S; Chen, H; Johnson, ML | 3 |
Amin, DF; Egberts, AC; Gardarsdottir, H; Heerdink, ER; Taxis, K; Wouters, H | 1 |
Ahlgren, J; Fredriksson, I; Garmo, H; Holmberg, L; Sund, M; Valachis, A; Weinman, J | 1 |
Ciliberto, M; De Crescenzo, F; Ebmeier, KP; Janiri, L; Menghini, D; Treglia, G | 1 |
Derijks, HJ; Grootens, K; Jessurun, N; Mikes, O; Otten, LS; van Marum, RJ; van Puijenbroek, EP; Vermeulen Windsant, A | 1 |
Chen, J; Deng, X; Fang, L; Lei, T; Lei, Y; Qu, Z; Zhang, L; Zhao, X; Zhong, J; Zhou, C; Zou, B | 1 |
Bots, CP; Brand, HS; van Nieuw Amerongen, A | 1 |
Evans, RW; Rosen, N | 1 |
Kelly, BD | 1 |
Deussing, JM; Henniger, MS; Holsboer, F; Kühne, C; Ohl, F; Paez-Pereda, M; Panhuysen, M; Pohl, T; Pütz, B; Sillaber, I | 1 |
Bespalov, AY; Gross, G; Mezler, M; Schoemaker, H; Sukhotina, IA; van Gaalen, MM; Wicke, K | 1 |
DU, HG; Fu, XC; Ma, GY; Zheng, H | 1 |
Caccia, S; Calcagno, E; Canetta, A; Cervo, L; Fracasso, C; Guzzetti, S; Invernizzi, RW; Sacchetti, G | 1 |
Breuer, ME; Campbell, U; Chan, JS; Groenink, L; Hanania, T; Korte, SM; Olivier, B; Oosting, RS; Schreiber, R; Snoeren, EM; Waldinger, M | 1 |
Irahara, M; Kase, Y; Noguchi, M; Numata, S; Ohmori, T; Tsuchiya, N; Uemura, H; Ueno, S; Yamada, M; Yasui, T; Yuzurihara, M | 1 |
Baldwin, DS; Boulenger, JP; Kasper, S; Larsson Lönn, S | 1 |
David, DJ; Deltheil, T; Gardier, AM; Hen, R; Reperant, C; Tanaka, K | 1 |
Glubb, DM; Joyce, PR; Kennedy, MA; McHugh, PC; Rogers, GR | 1 |
Croghan, TW; Daniel, G; Erder, MH; Esposito, D; Stoto, MA; Wahl, P | 1 |
Bienfait, K; Buyske, S; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M | 1 |
Chiocchetti, B; Melani, F; Muscas, GC; Rosati, E | 1 |
Aznar, S; Knudsen, GM; Licht, CL; Marcussen, AB; Overstreet, DH; Wegener, G | 1 |
De Koning, FH; Derijks, HJ; Egberts, AC; Heerdink, ER; Janknegt, R; Krekels, MM; Looij, BJ | 1 |
Lazzeroni, LC; Murphy, GM; Ryan, HS; Sarginson, JE; Schatzberg, AF | 1 |
Goldstein, I; Kellner, CH; Korda, JB; Pfaus, JG | 1 |
Ceylan, ME; Ozer, U; Turkcan, A | 1 |
Belitser, SV; Egberts, TC; Schobben, AF; Ververs, FF; Visser, GH; Voorbij, HA; Zwarts, P | 1 |
Corti, N; Elke, B; Locher, P; Wagner, CC | 1 |
Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
Governale, L; Hammad, TA; Kaplan, S; Mosholder, AD; Pamer, CA; Rochester, G; Wu, YT | 1 |
Chen, W; Geng, D; Huang, Y; Li, Y; Shi, X; Wu, X | 1 |
Gay, BM; Nogueira, CW; Prigol, M; Stein, AL | 1 |
Ershoff, BD; Lazzeroni, LC; Murphy, GM; Ryan, HS; Sarginson, JE; Schatzberg, AF | 1 |
Bishop, JR; Ellingrod, VL; Keiser, MJ; Thomas, KL | 1 |
Antonioli, L; Blandizzi, C; Colucci, R; Corona, T; Fornai, M; Mantarro, S; Montagnani, S; Pergola, A; Ruggiero, E; Scollo, C; Testi, A; Tuccori, M | 1 |
Einarson, A | 1 |
Fukui, N; Ono, S; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
Chen, WQ; Li, L; Lubec, G; Sartori, SB; Singewald, N; Whittle, N; Yang, JW | 1 |
De Keyser, J; Glazenborg, A; Koch, MW; Mostert, J; Uyttenboogaart, M | 1 |
Franco Hidalgo, S; Ginés Santiago, A; Nalotto, L; Prieto De Paula, JM | 1 |
Hata, M; Kawachi, H; Minami, K; Murakami, T; Sezai, A; Shiono, M; Takasaka, A; Wakui, S; Yagi, Y; Yoshitake, I | 1 |
Fang, Y; Jia, Y; Lian, Y; Wei, J; Xu, Y; Zeng, Z; Zhang, L; Zhao, X; Zhu, H | 1 |
DeRogatis, LR; Fabre, LF; Smith, LC | 1 |
Fitzgerald, P; Hannon, B; Murphy, M | 1 |
Kaneda, A; Kaneko, S; Nakagami, T; Sato, Y; Yasui-Furukori, N | 1 |
Cuestas, E; Cuestas, ME | 1 |
Bermudez, I; Franklin, M; Gaburro, S; Murck, H; Singewald, N | 1 |
Gibiino, S; Serretti, A | 1 |
Barbato, A; Bortolotti, A; D'Avanzo, B; Fortino, I; Franchi, C; Merlino, L; Nobili, A; Parabiaghi, A; Tettamanti, M | 1 |
Goto, F; Ogawa, K; Tsutsumi, T | 1 |
Bazanella Sampaio, T; Mozzaquatro Gai, B; Nogueira, CW; Pinton, S; Trevisan da Rocha, J; Zeni, G | 1 |
Khasanov, NR; Khasanova, DR; Oslopov, VN; Safiullina, AA; Zhitkova, IuV | 1 |
Dilillo, D; Penagini, F; Pogliani, L; Schneider, L; Zuccotti, GV | 1 |
Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Imperadore, G; Purgato, M; Signoretti, A; Trespidi, C; Watanabe, N | 1 |
Fiscella, K; Heckler, C; Innominato, PF; Janelsins, M; Kesler, S; Manber, R; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Roth, T; Sprod, LK | 1 |
Hartmann, J; Holsboer, F; Labermaier, C; Liebl, C; Marinescu, D; Müller, MB; Scharf, SH; Schmidt, MV; Uhr, M; Wagner, KV; Wang, XD | 1 |
Baldo, P; Cecco, S; Doree, C; McFerran, D; Molin, P | 1 |
Komaroff, AL | 1 |
Andrade, C | 1 |
Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C | 1 |
Bhatt, S; Devadoss, T; Jindal, A; Kumar, B; Mahesh, R; Pandey, DK | 1 |
Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE | 1 |
Blum, WF; Colla, M; Daseking, E; Deuschle, M; Gilles, M; Heuser, I; Kopf, D; Krumm, B; Lederbogen, F; Schilling, C; Weber-Hamann, B; Wudy, SA | 1 |
Li, L; Lin, M; Qian, MC; Shen, XH; Sun, JS; Yang, JH; Zhang, J; Zhong, H | 1 |
Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Tetsuo, S | 1 |
Chen, JQ; Huang, Y; Lin, WR; Wang, SX | 1 |
Cunha, MP; Machado, DG; Oliveira, Á; Pazini, FL; Rodrigues, AL | 1 |
Gouma, DJ; Koopman, MM; Levi, MM; Sewnath, ME; van Hillegersberg, R | 1 |
Orr, KG; Osborne, SF; Stafford, L | 1 |
Davenport, E; Velamoor, R | 1 |
Christensen, J; Clemmensen, PM; Dalsgaard, NJ; Dam, H; Hindberg, I; Lunde, M; Mellerup, E; Plenge, P; Rasmussen, A | 1 |
Chaudhry, HR; Qureshi, Z; Tareen, IA; Yazdani, I | 1 |
Boutilier, AS; Gardner, DM | 1 |
Landgraf, R | 1 |
Green, B | 1 |
Bush, VL; Fone, KC; Marsden, CA; Middlemiss, DN | 1 |
Eriksson, JG; Paile-Hyvärinen, M; Wahlbeck, K | 2 |
Lanchote, VL; Queiroz, RH; Zainaghi, IA | 1 |
Abbott, A | 1 |
Hadasová, E; Zourková, A | 1 |
Bourin, M; Dailly, E; David, DJ; Hascoët, M; Ripoll, N | 1 |
Lebert, F | 1 |
Kremer, C; Murphy, GM; Rodrigues, H; Schatzberg, AF | 1 |
Miller, A; Musselman, DL; Somerset, WI; Stout, SS | 1 |
Capuron, L; Fuchs, D; Lawson, DH; Miller, AH; Musselman, DL; Nemeroff, CB; Neurauter, G | 1 |
Broocks, A; Hohagen, F; Kordon, A | 1 |
Brooks, SJ; Krulewicz, SP; Kutcher, S | 1 |
Andrews, PL; Banerjee, TK; Flynn, PJ; Hickok, JT; Hynes, HE; King, DK; Kirshner, JJ; Morrow, GR; Raubertas, RF; Roscoe, JA | 1 |
Hausner, RS | 1 |
Rosner, MH | 1 |
Kondro, W; Sibbald, B | 1 |
Katsu, H; Nakayama, K; Ochiai, Y; Okino, S; Wakutsu, N | 1 |
Cryan, JF; Dalvi, A; Friedland, JC; Hirsch, BR; Jin, SH; Lucki, I; O'Leary, OF; Ouyang, M; Page, ME; Thomas, SA | 1 |
Jägestedt, M; von Bahr, C | 1 |
Wadman, M | 1 |
Horii, A; Kitahara, T; Kubo, T; Mitani, K; Takeda, N; Uno, A | 1 |
Ramchandani, P | 1 |
Arita, S; Morishita, S | 3 |
Agren, H; Hägglöf, B; Lundin, B; Waern, M | 1 |
Akinci, A; Kaymak, SU; Onat, AM; Ozçakar, L; Ureten, K | 1 |
Baldwin, DS; Bradley, BP; Brodrick, P; Mogg, K | 1 |
Joo, MH; Kim, HJ; Kim, SG; Koo, JR; Lee, HS; Lee, SK; Lee, YK; Noh, JW; Oh, JE; Seo, JW; Son, BK; Yoon, JY | 1 |
Andrews, AM; Perez, XA | 1 |
Bushunow, P; Griggs, JJ; Hickok, JT; Matteson, SE; Morrow, GR; Mustian, KM; Qazi, R; Roscoe, JA; Smith, B | 1 |
Hamada, R; Matsuoka, H; Nakajima, T; Okatsu, H; Osame, M; Wakita, M | 1 |
Huande, L; Juan, H; Zhiling, Z | 1 |
Harrison, D; Meng, F; Mullins, CD; Shaya, FT; Wang, J | 1 |
Deuschle, M; Gilles, M; Härtter, S; Heuser, I; Hiemke, C; Kellner, S; Krumm, B; Shams, M | 1 |
Egberts, AC; Heerdink, ER; Hugtenburg, JG; van Geffen, EC; van Hulten, RP | 1 |
Aursnes, I; Gaasemyr, J; Natvig, B; Tvete, IF | 1 |
Anghelescu, IG; Regen, F | 1 |
Briley, KA; Goodale, ES; Gopal, KV; Hendea, OM | 1 |
Goldney, RD | 1 |
Leonard, BE; Myint, AM; O'Mahony, SM; Steinbusch, H | 1 |
Kim, JJ; Kim, TS; Lee, C; Lee, CU; Lee, KU; Lee, SJ; Pae, CU; Paik, IH | 1 |
Gorodnichev, AV; Kostiukova, EG; Mosolov, SN; Timofeev, IV | 1 |
Dauphin, A; Gruwez, B; Tod, M | 1 |
Hasegawa, H; Hirose, S; Lin, QS; Nakamura, K; Nishimura, H; Ohashi, A; Ohtsuji, M; Sawabe, K; Sugawara, Y; Tsurui, H; Xiu, Y | 1 |
Davies, JT; Dunner, DL; Lipschitz, A; Pitts, CD | 1 |
Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R | 1 |
Bron, MS; Meng, F; Mullins, CD; Shaya, FT; Wang, J | 1 |
Friede, T; Kieser, M | 1 |
Chen, S; Gao, F; Manatunga, AK | 1 |
Bruce, KR; Israel, M; Ng Ying Kin, NM; Steiger, H | 1 |
Carluer, L; Defer, GL; Schupp, C | 1 |
Bourin, M; Chenu, F; Dailly, E | 1 |
Mani, H; Matsubara, H; Sakamoto, T; Sakatani, T; Shirayama, T; Yamamoto, T | 1 |
Ivanets, NN; Kinkul'kina, MA | 1 |
Baxter, LR; Brody, AL; Maidment, KM; Saxena, S | 1 |
Himei, A; Okamura, T | 1 |
Azuma, J; Fukuda, K; Fukuda, T; Ikenaga, Y; Kato, M; Kinoshita, T; Nobuhara, K; Okugawa, G; Takekita, Y; Wakeno, M; Yamashita, M | 1 |
García-Hernández, MJ; Kotzalidis, GD; Persechino, S; Ricciardi, A; Ruberto, A; Ruiz-Doblado, S; Tatarelli, R; Trevisi, M | 1 |
Lathi, RB; Shahine, LK | 1 |
Begley, AE; Dew, MA; Houck, PR; Mazumdar, S; Mulsant, BH; Reynolds, CF; Scott, J; Tang, G | 1 |
Berman, N; Bowden, CL; Frazer, A; Katz, MM | 1 |
Anghelescu, IG; Kieser, M; Klement, S; Kohnen, R; Szegedi, A | 1 |
Hamada, Y; Inatsugi, Y; Kusunoki, S; Miyamoto, K; Suzuki, H | 1 |
Hirayasu, Y; Karashima, A; Otsuka, T; Shioya, H; Sugiyama, N; Togo, T; Uehara, K; Yoshimi, A | 1 |
Aldushin, AA; Avedisova, AS; Brodin, VI | 1 |
Calgüneri, M; Ertenli, I; Kaymak, SU; Kiraz, S; Onat, AM; Ozçakar, L; Oztürk, MA; Ureten, K | 1 |
Hoelzl, U; Landgraf, R; Muigg, P; Neumann, I; Palfrader, K; Singewald, N; Wigger, A | 1 |
Andor, G; Harcos, P; Horváth, S; Karányi, Z; Nagy, Z; Németh, G | 1 |
Abe, T; Kato, S; Onishi, Y; Yamamoto, K | 1 |
Fujito, H; Kamikawa, H; Li, G; Maekawa, A; Oku, E; Somehara, T; Tatebayashi, H; Tsuruta, T; Ueki, H; Yamada, S; Yang, C | 1 |
Aubry, JM; Bertschy, G; Bondolfi, G; Eap, CB; Gervasoni, N; Gex-Fabry, M | 1 |
Ahmed, M; Parameshwaran, A; Swamy, P | 1 |
Cines, M; Gottlieb, SS; Greenberg, N; Katzen, S; Kop, WJ; Marshall, J; Minshall, S; Thomas, SA; Vesely, MR | 1 |
Andreatini, R; Casarotto, PC | 1 |
Boncompagni, G; Ferranti, A; Furlanetto, S; Mandrioli, R; Mercolini, L; Raggi, MA | 1 |
Bar-Oz, B; Bérard, A; Boskovic, R; Einarson, A; Einarson, T; Koren, G; Malm, H; O'Brien, L | 1 |
Dew, MA; Dombrovski, AY; Houck, PR; Lenze, EJ; Mulsant, BH; Pollock, BG; Reynolds, CF | 1 |
Chen, ZQ; Ji, JL; Liu, WJ; Mei, QY; Pan, JY; Tao, M; Wang, YP; Wei, J; Zhang, N; Zhao, ZX; Zheng, AL | 1 |
Bekele, NB; Shih, YC; Xu, Y | 1 |
Gong, SH; Liu, JQ; Liu, JS; Liu, S; Shi, ZY; Zhang, GJ | 1 |
Aviv, A; Barak, Y; Mazeh, D; Shahal, B; Zemishlani, H | 1 |
Babak, S; Bergman, U; Bertilsson, L; Boldueva, S; Burbello, A; Goryachkina, K | 1 |
Aichhorn, W; Bitterlich, W; Bondy, B; Geretsegger, C; Stelzig, R; Stuppaeck, C | 1 |
Barbui, C; Cipriani, A; Furukawa, TA | 1 |
Blackwood, D; Day, RK; Matthews, K; Reid, IC; Smith, D; Smith, G; Wilkie, MJ; Wolf, CR | 1 |
Cohen, LS; Joffe, H; Petrillo, L; Rydzewski, M; Soares, CN; Somley, B; Viguera, AC; Yehezkel, R | 1 |
Bravo-Mehmedbasić, A; Dzubur-Kulenović, A; Kucukalić, A | 1 |
Akishita, M; Eto, M; Ota, H; Ouchi, Y; Yamaguchi, K; Yamaguchi, Y | 1 |
Aisa, B; Del Rio, J; Elizalde, N; Gil-Bea, FJ; Lasheras, B; Ramírez, MJ; Tordera, RM | 1 |
Janne, P; Lejeune, D; Reynaert, C; Vause, M; Zdanowicz, N | 1 |
Clayton, AH; McGarvey, EL; Owens, JE | 1 |
Fartacek, R; Geretsegger, C; Heim, M; Mair, M; Platz, T; Stuppaeck, CH | 1 |
Gagiano, CA | 1 |
Feighner, JP | 1 |
Alarcón, J; Cabrera-Valdivia, F; García-Albea, E; Jiménez-Jiménez, FJ; Martínez-Junquera, G; Tejeiro, J | 1 |
Meyer, C | 1 |
Gammon, GD | 1 |
Chan, CH; Chiu, HJ; Hong, CJ | 1 |
Petty, KJ | 1 |
van Campen, JP; Voets, AJ | 1 |
Hayashi-Kuwabara, Y; Ikeda, Y; Izumi, J; Kiuchi, Y; Oguchi, K; Tanaka, Y; Washizuka, M; Yoshinaga, K | 1 |
Meier, E; Sánchez, C | 1 |
Gambini, O; Garghentini, G; Grassi, B; Lazzarin, A; Scarone, S | 1 |
Oldroyd, J | 1 |
Alvarez, P; Arranz, B; Menchón, JM; Navarro, MA; Oros, M; Rosel, P; Vallejo, J | 1 |
Costentin, J; Passera, G; Vaugeois, JM; Zuccaro, F | 1 |
Harry, B; Zimmerschied, JA | 1 |
György, S; Kecskés, I; Kiss, GH; Pestality, P; Rihmer, Z | 1 |
Cooper, TA; Gibbons, RB; O'Brien-Falls, K; Valcour, VG | 1 |
Hengeveld, MW; Tuyl, JP; Van der Mast, RC; Van Kempen, GM; Verkes, RJ; Zwinderman, AH | 1 |
Loge, JH; Ramstad, K; Sponheim, E | 1 |
Buchalter, EN; Giambanco, V; Lantz, MS | 1 |
Altamura, AC; Bignotti, S; Curreli, R; Pioli, R; Tura, G | 1 |
Cryan, JF; Leonard, BE; McGrath, C; Norman, TR | 2 |
Bourin, M; Redrobe, JP | 1 |
Béïque, JC; Blier, P; de Montigny, C; Debonnel, G | 1 |
Burke, WJ; Frank, MG; Hendricks, SE; Johnson, DR; Wieseler, JL | 1 |
Navarro, R; Spangler, M; Valler, WE | 1 |
Cohen, LJ | 1 |
Draper, B; Meares, S | 1 |
Bell, C; Nutt, D | 1 |
Christensen, HD; Coleman, FH; Gonzalez, CL; Rayburn, WF | 1 |
Hartman, EE; Parker, RA | 1 |
Crawford, J; Ellis, MJ; Hanfelt, JJ; Hayes, DF; Isaacs, C; Kramer, R; Lawrence, W; Rowland, J; Stearns, V | 1 |
Gregson, J | 1 |
Fagan, M | 1 |
Freisleder, FJ; Mayer-Rosa, J; Rüth, U; Schlamp, D | 1 |
Barrett, J; Cornell, J; Frank, E; Katon, W; Oxman, T; Sengupta, A; Sullivan, M; Williams, JW | 1 |
Antonini, A; Canesi, M; Mariani, CB; Pezzoli, G; Tesei, S; Zecchinelli, A | 1 |
Fortmann, SP; Hayward, C; Killen, JD; Rothman, M; Schatzberg, AF; Strausberg, L; Sussman, L; Varady, A | 1 |
Dew, MA; Hernandez, CR; Houck, PR; Mulsant, B; Pollock, BG; Reynolds, CF; Smith, GS | 1 |
Leard-Hansson, J | 1 |
Terluin, B; van Hout, H | 1 |
Bird, H; Broggini, M | 1 |
Robb-Nicholson, C | 1 |
Watson, S; Young, A | 1 |
Artigas, F; Colombo, C; Fazio, F; Gobbo, C; Messa, C; Moresco, R; Smeraldi, E; Zanardi, R | 1 |
Erazo, N; Greil, W; Grohmann, R; Horvath, A; Sassim, N | 1 |
Goicoechea, C; Martín, MI; Ormazábal, MJ; Sánchez, E | 1 |
Cassano, GB; Conti, L; Dell'Osso, L; Gemignani, A; Marazziti, D; Pfanner, C; Presta, S; Rossi, A | 1 |
Cook, IA; Leuchter, AF | 1 |
Agid, O; Lerer, B; Shalev, AY | 1 |
Barrett, JE; Cornell, JE; Frank, E; Hegel, MT; Katon, W; Oxman, TE; Sengupta, AS; Sullivan, M; Williams, JW | 1 |
McNeil, C | 1 |
Nakash, R; Overstreet, DH; Yadid, G; Zangen, A | 1 |
Kuboki, T | 1 |
Boskailo, E; Djuric-Bijedic, Z; Lewis, J; Pavkovic, I; Smajkic, A; Weine, S | 1 |
Freydl, K; Hasegawa, S; Hennegan, E; Hilchie-Schmidt, C; Hines, D; Iwata, J; Kappler, R; Mok, C; Plotkin, BJ; Raffaelli, D; Rodos, JJ; Schrage, M | 1 |
Antonucci, G; Bragoni, M; Coiro, P; De Angelis, D; Grasso, MG; Morelli, D; Paolucci, S; Rizzi, F; Troisi, E | 1 |
Li, C; Liu, M; Wu, W | 1 |
Bensasi, S; Houck, PR; Mazumdar, S; Miller, MD; Mulsant, BH; Nebes, R; Pollock, BG; Reynolds, CF; Stack, J; Sweet, RA | 1 |
Contu, A; Moslinger-Gehmayr, R; Pezzella, G | 1 |
Arbuzov, AL; Litvintsev, SV; Mironychev, GN; Reznik, AM | 1 |
Mynors-Wallis, LM; Thornett, AM | 1 |
Azadian, AG; Warnock, CA | 1 |
Ismail, M; Lyster, G | 1 |
Jacobsen, PB; Minton, S; Moncello, J; Weitzner, MA | 1 |
Dimidjian, S; Katon, W; Schmaling, KB; Sullivan, M | 1 |
Dunbar, GC; Stoker, MJ; Tignol, J | 1 |
Edwards, E; Harkins, K; Henn, F; Wright, G | 1 |
Brøsen, K; Eshøj, O; Gram, LF; Mogensen, EF; Sindrup, SH | 1 |
Westwick, F | 1 |
41 review(s) available for paroxetine and Depression
Article | Year |
---|---|
Paroxetine combined with traditional chinese medicine prescriptions in the treatment of postpartum depression: A systematic review of randomized controlled trials.
Topics: Depression; Depression, Postpartum; Female; Humans; Medicine, Chinese Traditional; Paroxetine; Prescriptions; Randomized Controlled Trials as Topic | 2022 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Fluoxetine; Humans; Imipramine; Network Meta-Analysis; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2022 |
The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson's disease: A meta-analysis.
Topics: Control Groups; Depression; Humans; Mental Status and Dementia Tests; Parkinson Disease; Paroxetine | 2023 |
Effectiveness of Paroxetine for Poststroke Depression: A Meta-Analysis.
Topics: Affect; Antidepressive Agents, Second-Generation; Depression; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Stroke; Time Factors; Treatment Outcome | 2020 |
In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis.
Topics: Depression; Dose-Response Relationship, Drug; Fluoxetine; Humans; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2020 |
Interventions for treating anxiety after stroke.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Buspirone; Depression; Humans; Middle Aged; Paroxetine; Pilot Projects; Psychotherapy; Randomized Controlled Trials as Topic; Relaxation Therapy; Stroke | 2017 |
What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence.
Topics: Adult; Anxiety; Citalopram; Depression; Female; Humans; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Serotonin | 2017 |
Advances in Pharmacotherapy of Late-Life Depression.
Topics: Antidepressive Agents; Aripiprazole; Depression; Depressive Disorder; Drug Resistance; Duloxetine Hydrochloride; Humans; Paroxetine; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Vortioxetine | 2018 |
Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease.
Topics: Antidepressive Agents, Tricyclic; Depression; Dizziness; Dyspnea; Exercise Tolerance; Forced Expiratory Volume; Humans; Nausea; Nortriptyline; Paroxetine; Placebos; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2018 |
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence; Thiophenes; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Paroxetine; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2013 |
A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
Topics: Allosteric Site; Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder, Major; Drug Interactions; Evidence-Based Medicine; Humans; Models, Biological; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2014 |
Paroxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Depression; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2014 |
The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Anxiety Disorders; Clinical Trials as Topic; Depression; Double-Blind Method; Humans; Panic Disorder; Paroxetine; Placebos; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2014 |
Women's health 2015: an update for the internist.
Topics: Clinical Competence; Depression; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Women's Health | 2015 |
Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Humans; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2016 |
May selective serotonin reuptake inhibitors (SSRIs) provide some benefit for the treatment of schizophrenia?
Topics: Antidepressive Agents; Antipsychotic Agents; Depression; Humans; Paroxetine; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2016 |
Is
Topics: Aged; Aging; Blood Glucose; Brain; Case-Control Studies; Depression; Fluorodeoxyglucose F18; Humans; Paroxetine; Positron-Emission Tomography; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sleep Deprivation | 2017 |
Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Clinical Trials as Topic; Data Interpretation, Statistical; Depression; Humans; Paroxetine; Reproducibility of Results; Sensitivity and Specificity; Sertraline; Venlafaxine Hydrochloride | 2017 |
[Frequent drug interactions in old age].
Topics: Adrenergic beta-Antagonists; Age Factors; Antihypertensive Agents; Cytochrome P-450 Enzyme System; Depression; Diuretics; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Humans; Metoprolol; Paroxetine; Polypharmacy; Risk Factors; Sulfonamides; Torsemide | 2009 |
Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.
Topics: Abnormalities, Drug-Induced; Cardiovascular Abnormalities; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Humans; Maternal-Fetal Exchange; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Sertraline; Teratogens | 2010 |
Pharmacologic treatment of depression in multiple sclerosis.
Topics: Adult; Antidepressive Agents; Depression; Desipramine; Humans; Multiple Sclerosis; Paroxetine; Randomized Controlled Trials as Topic | 2011 |
Paroxetine for the treatment of depression: a critical update.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Evidence-Based Medicine; Humans; Paroxetine; Patient Selection; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2012 |
Citalopram versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depression; Humans; Morpholines; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Antidepressants for patients with tinnitus.
Topics: Amitriptyline; Antidepressive Agents; Depression; Humans; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Tinnitus; Trazodone; Trimipramine | 2012 |
Duloxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Desvenlafaxine Succinate; Dibenzothiazepines; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Stroke; Stroke Rehabilitation | 2012 |
Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence-based pharmacotherapeutic case report.
Topics: Contraindications; Depression; Drug Interactions; Humans; Male; Middle Aged; Migraine Disorders; Oxazolidinones; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Serotonin Syndrome; Tryptamines | 2003 |
Focus on paroxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depression; Drug Interactions; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Substance Withdrawal Syndrome; Treatment Outcome | 2003 |
[Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias].
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Dementia; Depression; Fluoxetine; Humans; Neuropsychological Tests; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Time Factors; Trazodone | 2003 |
Paroxetine use in medically ill patients.
Topics: Antidepressive Agents, Second-Generation; Depression; Disease; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2003 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior Therapy; Child; Citalopram; Clomipramine; Depression; Diagnosis, Differential; Eczema; Family Practice; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychotherapy; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline; Surveys and Questionnaires; Time Factors; Trichotillomania | 2003 |
Suicide attempts in clinical trials with paroxetine randomised against placebo.
Topics: Adult; Bayes Theorem; Depression; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted | 2005 |
Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials.
Topics: Adolescent; Adult; Aged; Delayed-Action Preparations; Depression; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2005 |
Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors.
Topics: Abnormalities, Drug-Induced; Adult; Amniocentesis; Antidepressive Agents, Second-Generation; Anxiety; Depression; Electrocardiography; Female; Humans; Infant, Newborn; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimesters; Ultrasonography | 2007 |
Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials.
Topics: Acute Disease; Depression; Humans; Paroxetine; Patient Compliance; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2008 |
[Clinical effects of serotonin reuptake inhibitors--a review].
Topics: Depression; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1994 |
[Early internal treatment of mild depression].
Topics: Depression; Fluvoxamine; Health Knowledge, Attitudes, Practice; Humans; Paroxetine; Physicians, Family; Referral and Consultation; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Social Support; Suicide Prevention | 2001 |
Paroxetine in the treatment of melancholia and severe depression.
Topics: Adult; Depression; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales | 1992 |
Depression and selective serotonin reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depression; Fluoxetine; Humans; Imipramine; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Paroxetine; Piperidines; Serotonin Antagonists | 1990 |
78 trial(s) available for paroxetine and Depression
Article | Year |
---|---|
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
Topics: Acetamides; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Paroxetine | 2021 |
Network dynamics of depressive symptoms in antidepressant medication treatment: secondary analysis of eight clinical trials.
Topics: Antidepressive Agents; Depression; Fluoxetine; Humans; Paroxetine; Prospective Studies | 2021 |
Affect, interpersonal behaviour and interpersonal perception during open-label, uncontrolled paroxetine treatment of people with social anxiety disorder: a pilot study
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Humans; Interpersonal Relations; Male; Middle Aged; Paroxetine; Phobia, Social; Pilot Projects; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Social Behavior; Social Perception; Young Adult | 2018 |
Promoting the well-being of mothers with multidisciplinary psychosocial interventions in the perinatal period.
Topics: Adult; Antidepressive Agents; Anxiety; Combined Modality Therapy; Depression; Depression, Postpartum; Female; Humans; Longitudinal Studies; Mothers; Paroxetine; Patient Acceptance of Health Care; Perinatal Care; Pregnancy; Pregnancy Complications; Psychotherapy; Risk Factors; Sertraline; Treatment Outcome | 2019 |
Dynamics and persistence of CYP2D6 inhibition by paroxetine.
Topics: Adolescent; Adult; Aged; Alprazolam; Anxiety; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Dextromethorphan; Dextrorphan; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Young Adult | 2013 |
Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy.
Topics: Affect; Antidepressive Agents; Anxiety; Cognition; Cognitive Behavioral Therapy; Depression; Humans; Paroxetine; Suicidal Ideation; Symptom Assessment | 2013 |
Effects of electro-acupuncture on personality traits in depression: a randomized controlled study.
Topics: Case-Control Studies; Demography; Depression; Electroacupuncture; Female; Humans; Male; Middle Aged; Paroxetine; Patient Dropouts; Personality; Personality Inventory; Psychiatric Status Rating Scales | 2013 |
Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Germany; Humans; Lavandula; Male; Middle Aged; Oils, Volatile; Paroxetine; Plant Oils; Psychiatric Status Rating Scales; Quality of Life; Remission Induction; Treatment Outcome | 2014 |
Gains in employment status following antidepressant medication or cognitive therapy for depression.
Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Employment; Follow-Up Studies; Humans; Odds Ratio; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2015 |
Trajectories of recovery in depressed Parkinson's disease patients treated with paroxetine or venlafaxine.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Venlafaxine Hydrochloride | 2016 |
Comparative Efficacy of Newer Antidepressants in Combination with Pregabalin for Fibromyalgia Syndrome: A Controlled, Randomized Study.
Topics: Adult; Amitriptyline; Antidepressive Agents; Depression; Drug Therapy, Combination; Female; Fibromyalgia; Humans; Male; Middle Aged; Paroxetine; Pregabalin; Quality of Life; Venlafaxine Hydrochloride | 2017 |
Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss.
Topics: Adiposity; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Checklist; China; Depression; Dyspepsia; Female; Hormones; Humans; Intra-Abdominal Fat; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome; Weight Loss | 2016 |
Comparison of paroxetine and amitriptyline in the treatment of refractory globus pharyngeus.
Topics: Adult; Amitriptyline; Antidepressive Agents; Anxiety; China; Depression; Double-Blind Method; Female; Humans; Lansoprazole; Male; Middle Aged; Paroxetine; Pharyngeal Diseases; Prospective Studies; Proton Pump Inhibitors; Psychiatric Status Rating Scales; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2016 |
Changes in circulating cytokine levels in midlife women with psychological symptoms with selective serotonin reuptake inhibitor and Japanese traditional medicine.
Topics: Administration, Oral; Climacteric; Cytokines; Depression; Drugs, Chinese Herbal; Hot Flashes; Humans; Magnoliopsida; Medicine, East Asian Traditional; Middle Aged; Paroxetine; Phytotherapy; Plant Extracts; Selective Serotonin Reuptake Inhibitors | 2009 |
Superiority of escitalopram to paroxetine in the treatment of depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paroxetine; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depression; Disability Evaluation; Double-Blind Method; Female; Humans; Male; Middle Aged; Nortriptyline; Parkinson Disease; Paroxetine; Psychiatric Status Rating Scales; Quality of Life; Recurrence; Treatment Outcome | 2009 |
FKBP5 polymorphisms and antidepressant response in geriatric depression.
Topics: Aged; Antidepressive Agents; Depression; Double-Blind Method; Female; Genetic Variation; Geriatrics; Humans; Male; Mianserin; Mirtazapine; Paroxetine; Polymorphism, Genetic; Sequence Analysis, DNA; Tacrolimus Binding Proteins; Treatment Outcome | 2010 |
Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.
Topics: Adult; Antidepressive Agents, Second-Generation; Cohort Studies; Cytochrome P-450 CYP2D6; Depression; Drug Monitoring; Female; Genotype; Humans; Middle Aged; Paroxetine; Pharmacogenetics; Pregnancy; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depression; Double-Blind Method; Female; Humans; Libido; Paroxetine; Psychiatric Status Rating Scales; Psychological Tests; Pyrimidines; Sexual Dysfunctions, Psychological; Treatment Outcome | 2011 |
The influence of personality factors on paroxetine response time in patients with major depression.
Topics: Adult; Aged; Antidepressive Agents; Character; Depression; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Personality; Personality Disorders; Personality Inventory; Predictive Value of Tests; Selective Serotonin Reuptake Inhibitors; Temperament; Treatment Outcome | 2011 |
Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Depression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasms; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders; Treatment Outcome; Young Adult | 2012 |
Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Biomarkers; Body Mass Index; Cyclohexanols; Depression; Female; Humans; Leptin; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Time Factors; Treatment Outcome; Up-Regulation; Venlafaxine Hydrochloride; Weight Gain; Young Adult | 2013 |
[Effects of apolipoprotein E genetic polymorphism on susceptibility of depression and efficacy of antidepressants].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Apolipoproteins E; Cyclohexanols; Depression; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2012 |
5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.
Topics: Analysis of Variance; Antidepressive Agents; Depression; Female; Fluvoxamine; Gene Frequency; Genotype; Humans; Japan; Logistic Models; Male; Paroxetine; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Serotonin Plasma Membrane Transport Proteins; Time Factors; Treatment Outcome | 2013 |
[Global improvement in agitated depression treated with the alliance therapy of acupuncture and seroxat and the observation of the quality of life].
Topics: Acupuncture Therapy; Adolescent; Adult; Antidepressive Agents; Combined Modality Therapy; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Quality of Life; Young Adult | 2012 |
Platelet serotonin transporter in stroke patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Binding, Competitive; Biomarkers; Blood Platelets; Carrier Proteins; Chronic Disease; Depression; Female; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Reference Values; Serotonin Plasma Membrane Transport Proteins; Stroke; Time Factors | 2003 |
Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2002 |
Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Glucose; Depression; Diabetes Mellitus, Type 2; Female; Humans; Middle Aged; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Single-Blind Method | 2003 |
Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Depression; Female; Genotype; Humans; Male; Middle Aged; Paroxetine; Phenotype; Sexual Dysfunctions, Psychological; Treatment Outcome | 2003 |
The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients.
Topics: Aged; Aged, 80 and over; Alleles; Antidepressive Agents; Apolipoproteins E; Chromatography, High Pressure Liquid; Cognition; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genotype; Geriatric Psychiatry; Humans; Male; Mianserin; Mirtazapine; Neuropsychological Tests; Paroxetine; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome | 2003 |
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Depression; Double-Blind Method; Female; Humans; Interferon-alpha; Kynurenine; Male; Melanoma; Middle Aged; Neopterin; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; Tryptophan | 2003 |
The Kutcher Adolescent Depression Scale: assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depression; Double-Blind Method; Female; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Reproducibility of Results | 2003 |
Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Depression; Double-Blind Method; Fatigue; Female; Humans; Male; Middle Aged; Neoplasms; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2003 |
Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Chi-Square Distribution; Cohort Studies; Cyclopropanes; Depression; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder.
Topics: Adult; Affect; Agoraphobia; Citalopram; Cognition; Cross-Sectional Studies; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychomotor Performance; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nutritional Status; Paroxetine; Renal Dialysis | 2005 |
Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Breast Neoplasms; Depression; Double-Blind Method; Fatigue; Female; Humans; Male; Middle Aged; Paroxetine; Placebos; Treatment Outcome | 2005 |
Paroxetine serum concentrations in depressed patients and response to treatment.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depression; Dose-Response Relationship, Drug; Electrochemistry; Female; Humans; Male; Middle Aged; Paroxetine; Severity of Illness Index; Time Factors; Treatment Outcome | 2005 |
Selective serotonin reuptake inhibitors treatment effects on auditory measures in depressed female subjects.
Topics: Acoustic Impedance Tests; Adult; Brain; Depression; Dichotic Listening Tests; Evoked Potentials, Auditory, Brain Stem; Female; Fluoxetine; Humans; Loudness Perception; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Speech Perception | 2005 |
[Comparative efficacy and tolerability of paroxetine and amitriptiline in long-term therapy preventing depressive recurrences].
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Data Interpretation, Statistical; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Quality of Life; Recurrence; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 2005 |
Risperidone in the treatment of psychotic depression.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Time Factors | 2006 |
Paroxetine treatment of compulsive hoarding.
Topics: Adult; Anxiety; Compulsive Behavior; Depression; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires | 2007 |
Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome.
Topics: Adult; Age Factors; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Depression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Retrospective Studies; Sex Factors; Substance Withdrawal Syndrome | 2006 |
Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Female; Humans; Hypericum; Male; Middle Aged; Paroxetine; Plant Extracts; Psychiatric Status Rating Scales; Secondary Prevention; Treatment Outcome | 2006 |
[Clinical effectiveness and safety of paroxetine in post-stroke depression: results from a phase 4, open label, multicenter clinical trial with 26 weeks of follow-up].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depression; Female; Follow-Up Studies; Humans; Hungary; Male; Middle Aged; Paroxetine; Prevalence; Quality of Life; Selective Serotonin Reuptake Inhibitors; Stroke; Time Factors; Treatment Outcome | 2006 |
Time course of response to paroxetine: influence of plasma level.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Time Factors | 2007 |
A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Delayed-Action Preparations; Depression; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Paroxetine; Pilot Projects; Quality of Life; Treatment Outcome | 2007 |
Determination of the antidepressant paroxetine and its three main metabolites in human plasma by liquid chromatography with fluorescence detection.
Topics: Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depression; Fluorescence; Humans; Paroxetine; Reproducibility of Results | 2007 |
Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial.
Topics: Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Depression; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Health Status Indicators; Humans; Male; Mental Health; Middle Aged; Paroxetine; Quality of Life | 2007 |
Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Follow-Up Studies; Humans; Interpersonal Relations; Male; Paroxetine; Psychotherapy, Brief; Quality of Life; Recurrence; Retrospective Studies; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2007 |
[Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study].
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Outcome Assessment, Health Care; Paroxetine; Pyridines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Zolpidem | 2007 |
Clinical observation on treatment of depression by electro-acupuncture combined with Paroxetine.
Topics: Adult; Combined Modality Therapy; Depression; Electroacupuncture; Female; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dizziness; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Male; Nausea; Paroxetine; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Xerostomia | 2007 |
Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Area Under Curve; Bradycardia; Cytochrome P-450 CYP2D6; Depression; Dose-Response Relationship, Drug; Drug Interactions; Female; Genotype; Heart Rate; Humans; Hypotension, Orthostatic; Male; Metoprolol; Middle Aged; Myocardial Infarction; Paroxetine | 2008 |
Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients.
Topics: Adult; Depression; Double-Blind Method; Drug Evaluation; Drug Synergism; Female; Humans; Inpatients; Male; Middle Aged; Paroxetine; Pindolol; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Statistics, Nonparametric; Time Factors | 2008 |
Paroxetine versus placebo for women in midlife after hormone therapy discontinuation.
Topics: Adult; Depression; Double-Blind Method; Estrogen Replacement Therapy; Female; Hot Flashes; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Treatment Outcome | 2008 |
Paroxetine in the treatment of post traumatic stress disorder: our experiences.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Dose-Response Relationship, Drug; Health Surveys; Humans; Outcome Assessment, Health Care; Paranoid Disorders; Paroxetine; Phobic Disorders; Stress Disorders, Post-Traumatic; Treatment Outcome | 2008 |
Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome.
Topics: Adult; Antidepressive Agents; Depression; Fluoxetine; Humans; Internal-External Control; Maprotiline; Paroxetine; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome | 1995 |
Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire.
Topics: Adult; Depression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Self-Assessment; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Time Factors | 1995 |
Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients.
Topics: Aged; Aging; Amitriptyline; Depression; Double-Blind Method; Female; Humans; Male; Paroxetine; Time Factors | 1995 |
Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depression; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1996 |
Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression.
Topics: Adult; Anger; Depression; Double-Blind Method; Female; Humans; Male; Mental Disorders; Paroxetine; Patient Dropouts; Personality Disorders; Placebos; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Suicide, Attempted; Treatment Outcome | 1998 |
Antidepressants augment natural killer cell activity: in vivo and in vitro.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Immunoassay; In Vitro Techniques; Killer Cells, Natural; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Stimulation, Chemical | 1999 |
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.
Topics: Adult; Aged; Anxiety; Breast Neoplasms; Confidence Intervals; Depression; Female; Hot Flashes; Humans; Menopause; Middle Aged; Paroxetine; Pilot Projects; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Surveys and Questionnaires; Survivors | 2000 |
Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Dysthymic Disorder; Family Practice; Female; Humans; Male; Paroxetine; Psychological Tests; Psychotherapy; Treatment Outcome | 2000 |
Tolerability of paroxetine in Parkinson's disease: a prospective study.
Topics: Aged; Antiparkinson Agents; Clinical Protocols; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2000 |
Nicotine patch and paroxetine for smoking cessation.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Paroxetine; Patient Compliance; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome | 2000 |
Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Arthritis, Rheumatoid; Depression; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Treatment Outcome | 2000 |
Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder.
Topics: Adult; Ambulatory Care; Depression; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Stress Disorders, Post-Traumatic; Treatment Outcome; Triiodothyronine | 2001 |
Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years.
Topics: Adolescent; Adult; Antidepressive Agents; Depression; Double-Blind Method; Dysthymic Disorder; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Primary Health Care; Problem Solving; Psychiatric Status Rating Scales; Psychotherapy; Remission Induction; Severity of Illness Index; Treatment Outcome | 2001 |
Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms.
Topics: Adult; Cyclohexanols; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Refugees; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Adjunctive osteopathic manipulative treatment in women with depression: a pilot study.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Double-Blind Method; Female; Humans; Manipulation, Orthopedic; Middle Aged; Osteopathic Medicine; Paroxetine; Physical Examination; Pilot Projects; Prospective Studies; Psychometrics; Psychotherapy; Treatment Outcome | 2001 |
A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Tricyclic; Depression; Double-Blind Method; Female; Humans; Male; Nortriptyline; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Breast Neoplasms; Depression; Double-Blind Method; Female; Humans; Middle Aged; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors; Treatment Outcome | 2001 |
Credibility of problem-solving therapy and medication for the treatment of depression among primary care patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Psychotherapeutic Processes; Time Factors; Treatment Outcome | 2002 |
A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Depression; Fatigue; Female; Hot Flashes; Humans; Middle Aged; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders | 2002 |
Response styles among patients with minor depression and dysthymia in primary care.
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Depression; Dysthymic Disorder; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Primary Health Care; Problem Solving; Treatment Outcome | 2002 |
The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.
Topics: Depression; Desipramine; Diabetic Neuropathies; Humans; Imipramine; Nervous System; Osmolar Concentration; Paroxetine; Piperidines; Serotonin Antagonists; Time Factors | 1990 |
218 other study(ies) available for paroxetine and Depression
Article | Year |
---|---|
A combination of P300 and eye movement data improves the accuracy of auxiliary diagnoses of depression.
Topics: Depression; Eye Movements; Humans; Paroxetine; Transcranial Magnetic Stimulation; Treatment Outcome | 2022 |
The network analysis of depressive symptoms before and after two weeks of antidepressant treatment.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2022 |
Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
Topics: Adult; Aged; Analgesics, Opioid; Cohort Studies; Comorbidity; Depression; Emergency Medical Services; Female; Fluoxetine; Hospitalization; Humans; Male; Middle Aged; Opiate Overdose; Oxycodone; Pain; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2022 |
Effects of Paroxetine on Plasma Levels of Vascular Endothelial Growth Factor in Patients with Major Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Vascular Endothelial Growth Factor A | 2022 |
Identification and investigation of depression-related molecular subtypes in inflammatory bowel disease and the anti-inflammatory mechanisms of paroxetine.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Depression; Humans; Inflammation; Inflammatory Bowel Diseases; Paroxetine; Tumor Necrosis Factor Inhibitors | 2023 |
Estimating the prevalence of depression using wastewater-based epidemiology: A case study in Qinghai Province, West China.
Topics: Antidepressive Agents; China; Depression; Paroxetine; Prevalence; Sertraline; Venlafaxine Hydrochloride; Wastewater; Water Pollutants, Chemical | 2023 |
The antidepressant-like effects of escitalopram in mice require salt-inducible kinase 1 and CREB-regulated transcription co-activator 1 in the paraventricular nucleus of the hypothalamus.
Topics: Animals; Antidepressive Agents; Depression; Escitalopram; Fluoxetine; Humans; Mice; Paraventricular Hypothalamic Nucleus; Paroxetine; Serotonin; Stress, Psychological | 2023 |
A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence.
Topics: Artificial Intelligence; Depression; Depressive Disorder, Major; Humans; Paroxetine; Randomized Controlled Trials as Topic | 2023 |
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.
Topics: Basal Ganglia; Basal Ganglia Diseases; Calcinosis; Depression; Diagnosis, Differential; Female; Humans; Mental Disorders; Middle Aged; Neurodegenerative Diseases; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Psychotropic Drugs; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Pharmacological; Depression; Depressive Disorder, Major; Female; Genotype; Humans; Male; Middle Aged; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2020 |
A novel stress re-stress model: modification of re-stressor cue induces long-lasting post-traumatic stress disorder-like symptoms in rats.
Topics: Animals; Anxiety; Behavior, Animal; Cognitive Dysfunction; Corticosterone; Cues; Depression; Disease Models, Animal; Electric Stimulation; Hypothalamo-Hypophyseal System; Male; Paroxetine; Rats; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic | 2020 |
Combination of mirtazapine and paroxetine: possible clinically demonstrated interaction?
Topics: Antidepressive Agents; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Humans; Mirtazapine; Paroxetine | 2019 |
Multinational Investigation of Fracture Risk with Antidepressant Use by Class, Drug, and Indication.
Topics: Aged; Antidepressive Agents; Depression; Female; Fractures, Bone; Humans; Male; North America; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Taiwan; United Kingdom; Venlafaxine Hydrochloride | 2020 |
Antidepressant action of transcranial direct current stimulation in olfactory bulbectomised adolescent rats.
Topics: Animals; Brain-Derived Neurotrophic Factor; Combined Modality Therapy; Depression; Disease Models, Animal; Male; Olfactory Bulb; Paroxetine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Transcranial Direct Current Stimulation | 2021 |
BiteStrip analysis of the effect of fluoxetine and paroxetine on sleep bruxism.
Topics: Adult; Anxiety; Dental Devices, Home Care; Depression; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep Bruxism; Treatment Outcome | 2017 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2017 |
Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function.
Topics: Animals; Citalopram; Depression; Fluoxetine; Hindlimb Suspension; Male; Mice, Inbred C57BL; Mice, Inbred DBA; Paroxetine; Protein Binding; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Species Specificity; Swimming; Synaptosomes | 2017 |
Depressive symptoms, monoamines levels, MAO-B activity and effect of treatment in a subset of depressed individuals from government sector hospital at Karachi.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Biomarkers; Case-Control Studies; Depression; Female; Fluoxetine; Homovanillic Acid; Hospitals, Public; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Monoamine Oxidase; Pakistan; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Suicidal Ideation; Treatment Outcome; Young Adult | 2017 |
Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Case-Control Studies; China; Cytokines; Depression; Depressive Disorder, Major; Female; Humans; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2018 |
Paroxetine blunts the corticosterone response to swim-induced stress and increases depressive-like behavior in a rat model of postpartum depression.
Topics: Animals; Corticosterone; Depression; Depression, Postpartum; Disease Models, Animal; Female; Male; Paroxetine; Peripartum Period; Postpartum Period; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress, Psychological; Swimming | 2018 |
[Exploring the clinical characters of Shugan Jieyu capsule through text mining].
Topics: Anxiety; Data Mining; Depression; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Fluoxetine; Humans; Paroxetine; Sertraline | 2017 |
Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily B; Depression; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Male; Paroxetine; Polymorphism, Single Nucleotide; Slovakia; Treatment Outcome | 2018 |
MicroRNA-451a, microRNA-34a-5p, and microRNA-221-3p as predictors of response to antidepressant treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Biomarkers; Case-Control Studies; Depression; Educational Status; Female; Gene Expression Profiling; Humans; Male; MicroRNAs; Paroxetine; Psychiatric Status Rating Scales; Real-Time Polymerase Chain Reaction; Suicidal Ideation; Treatment Outcome | 2018 |
Effectiveness of paroxetine in the treatment of poststroke depression.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Retrospective Studies; Stroke; Treatment Outcome | 2018 |
Alleviating Effect of Antidepressant Treatment on Psychiatric Symptoms and Cardiac Conditions in a Patient with Coronary Slow Flow Comorbid with Depression and Anxiety.
Topics: Antidepressive Agents; Anxiety; Comorbidity; Depression; Female; Humans; Middle Aged; Myocardial Infarction; Paroxetine | 2018 |
Cumulative Antidepressant Use and Risk of Dementia in a Prospective Cohort Study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Cholinergic Antagonists; Dementia; Depression; Female; Humans; Independent Living; Male; Paroxetine; Proportional Hazards Models; Prospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Time Factors; Washington | 2018 |
Perinatal exposure to the SSRI paroxetine alters the methylome landscape of the developing dentate gyrus.
Topics: Animals; Animals, Newborn; Antidepressive Agents; Behavior, Animal; Dentate Gyrus; Depression; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Female; Gene Expression; Male; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Selective Serotonin Reuptake Inhibitors; Sex Factors | 2019 |
Pharmacologic chaos: severe hypotension from interactions of anesthetics, marijuana, amphetamines, and paroxetine.
Topics: Adolescent; Amphetamines; Anesthesia; Anesthetics, Inhalation; Cannabis; Depression; Drug Interactions; Female; Humans; Hypotension; Marijuana Smoking; Pain, Postoperative; Paroxetine; Spinal Fusion; Substance Abuse Detection | 2019 |
Selective Serotonin Reuptake Inhibitors Aggravate Depression-Associated Dry Eye Via Activating the NF-κB Pathway.
Topics: Animals; Blotting, Western; Cells, Cultured; Cytokines; Depression; Dry Eye Syndromes; Enzyme-Linked Immunosorbent Assay; Epithelium, Corneal; Flow Cytometry; Humans; Immunohistochemistry; Male; NF-kappa B; Paroxetine; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Selective Serotonin Reuptake Inhibitors; Serotonin; Tears | 2019 |
Paroxetine
Topics: Antidepressive Agents; Depression; Double-Blind Method; Female; Humans; Middle Aged; Paroxetine; Postmenopause; Psychiatric Status Rating Scales; Retrospective Studies; Vortioxetine | 2019 |
Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Longitudinal Studies; Outcome Assessment, Health Care; Paroxetine; Placebos; Psychiatric Status Rating Scales; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index | 2019 |
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; Depression; Female; Fluoxetine; Follow-Up Studies; Humans; Logistic Models; Male; Mianserin; Middle Aged; Mirtazapine; Obesity; Paroxetine; Psychotherapy; Young Adult | 2013 |
Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: involvement of nitric oxide.
Topics: Animals; Antidepressive Agents; Brain; Compulsive Behavior; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Hippocampus; Immobility Response, Tonic; Male; Maze Learning; Nitric Oxide; Nitric Oxide Synthase Type II; Paroxetine; Purinergic Antagonists; Pyridoxal Phosphate; Rats; Receptors, Purinergic; Swimming | 2013 |
Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Fluoxetine; Guinea Pigs; Mice; Motor Activity; Olfactory Bulb; Paroxetine; Quinoxalines; Rats; Rats, Wistar; Serotonin 5-HT3 Receptor Antagonists; Swimming | 2013 |
Antidepressants and testicular cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; California; Case-Control Studies; Cohort Studies; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Testicular Neoplasms; Young Adult | 2014 |
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.
Topics: Aged; Antidepressive Agents; Anxiety; Cyclohexanols; Datasets as Topic; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Venlafaxine Hydrochloride | 2014 |
Dietary magnesium restriction reduces amygdala-hypothalamic GluN1 receptor complex levels in mice.
Topics: Amygdala; Analysis of Variance; Animals; Depression; Diet; Disease Models, Animal; Gene Expression Regulation; Hypothalamus; Magnesium; Magnesium Deficiency; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Paroxetine; Receptors, N-Methyl-D-Aspartate; Selective Serotonin Reuptake Inhibitors | 2015 |
Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.
Topics: Animals; Anticholesteremic Agents; Antidepressive Agents, Second-Generation; Blood Glucose; Cell Line; Depression; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Drug Interactions; Hypercholesterolemia; Insulin; Male; Paroxetine; Pravastatin; Rats; Rats, Sprague-Dawley; Serotonin | 2014 |
Stimulation of Sigma-1 Receptor Ameliorates Depressive-like Behaviors in CaMKIV Null Mice.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; CA3 Region, Hippocampal; Calbindins; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Dentate Gyrus; Depression; Fluvoxamine; Gene Expression Regulation; Immobilization; Long-Term Potentiation; Male; Maze Learning; Mice; Mice, Knockout; Nerve Tissue Proteins; Neurogenesis; Paroxetine; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Receptors, N-Methyl-D-Aspartate; Receptors, sigma; Sigma-1 Receptor | 2015 |
Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans.
Topics: Adult; Amitriptyline; Animals; Antidepressive Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Blood Cells; Depression; Depressive Disorder; Female; Humans; Leukocytes, Mononuclear; Male; Membrane Proteins; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Paroxetine; Rats, Sprague-Dawley; Stress, Psychological; Tacrolimus Binding Proteins; Young Adult | 2014 |
A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant.
Topics: Animals; Depression; Disease Models, Animal; Dorsal Raphe Nucleus; Drug Synergism; Electrophysiological Phenomena; Hippocampus; Male; Microdialysis; Ondansetron; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT3 Receptor Antagonists | 2015 |
FKBP5/FKBP51 enhances autophagy to synergize with antidepressant action.
Topics: Amitriptyline; Animals; Antidepressive Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Behavior, Animal; Depression; Electrophysiology; Gene Expression Regulation; HSP90 Heat-Shock Proteins; Humans; Immunoprecipitation; Membrane Proteins; Mice; Molecular Chaperones; Paroxetine; Phosphorylation; Tacrolimus Binding Proteins | 2015 |
Antidepressant treatment decreases daily salt intake and prevents heart dysfunction following subchronic aortic regurgitation in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Aortic Valve Insufficiency; Blood Pressure; Depression; Disease Models, Animal; Drinking; Echocardiography; Heart Rate; Male; Myocardium; Organ Size; Paroxetine; Potassium; Rats; Rats, Wistar; Sodium Chloride; Time Factors; Water-Electrolyte Balance | 2015 |
Clinical presentation and pharmacotherapy response in social anxiety disorder: The effect of etiological beliefs.
Topics: Adolescent; Adult; Anxiety; Depression; Emotions; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Paroxetine; Phobic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2015 |
Effects of amycenone on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Dose-Response Relationship, Drug; Interleukin-10; Lipopolysaccharides; Male; Mice; Paroxetine; Plant Extracts; Tumor Necrosis Factor-alpha | 2015 |
Paroxetine-Related Adult-Onset Tic Disorder: A Presentation of Primary Progressive Multiple Sclerosis.
Topics: Antidepressive Agents, Second-Generation; Brain; Depression; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis, Chronic Progressive; Paroxetine; Tic Disorders | 2015 |
Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Child, Preschool; Citalopram; Cohort Studies; Databases, Factual; Depression; Dose-Response Relationship, Drug; Drug Labeling; Drug Prescriptions; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Practice Guidelines as Topic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Suicide, Attempted; United States; United States Food and Drug Administration; Young Adult | 2016 |
Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; HEK293 Cells; Humans; Mice; Paroxetine; Phosphorylation; Tacrolimus Binding Proteins | 2015 |
Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: formulation, behavioural and biochemical estimation.
Topics: Administration, Intranasal; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Chemistry, Pharmaceutical; Depression; Disease Models, Animal; Emulsions; Female; Male; Paroxetine; Particle Size; Rats; Rats, Wistar; Swine | 2016 |
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cohort Studies; Depression; Female; Health Resources; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Paroxetine; Proportional Hazards Models; Survivors; Tamoxifen; United States | 2016 |
Use of antidepressants and breast cancer recurrence.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Depression; Female; Humans; Neoplasm Recurrence, Local; Paroxetine; Tamoxifen | 2016 |
Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats.
Topics: Adenine; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Fluoxetine; Food Preferences; Imipramine; Male; Motor Activity; Paroxetine; Rats; Reserpine; Sertraline; Venlafaxine Hydrochloride | 2016 |
A novel isoquinoline compound abolishes chronic unpredictable mild stress-induced depressive-like behavior in mice.
Topics: Adrenal Glands; Animals; Antidepressive Agents; Cytokines; Depression; Disease Models, Animal; Grooming; Hindlimb Suspension; Hormones; Locomotion; Male; Mice; Paroxetine; Prefrontal Cortex; Quinolines; Serotonin; Stress, Psychological; Swimming; Synaptosomes; Tritium | 2016 |
Ovariectomy changes the response to antidepressant drugs in tail suspension test in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Doxepin; Estrogens; Female; Hindlimb Suspension; Menopause; Mice; Mice, Inbred ICR; Ovariectomy; Paroxetine; Venlafaxine Hydrochloride | 2016 |
Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors.
Topics: Aged; Depression; Female; Hip Fractures; Humans; Male; Nursing Homes; Paroxetine; Retrospective Studies; Risk; Selective Serotonin Reuptake Inhibitors | 2016 |
Associations Between Personality Traits and Adherence to Antidepressants Assessed Through Self-Report, Electronic Monitoring, and Pharmacy Dispensing Data: A Pilot Study.
Topics: Adult; Antidepressive Agents; Depression; Female; Humans; Male; Medication Adherence; Middle Aged; Paroxetine; Personality; Pharmaceutical Services; Pilot Projects; Self Report | 2016 |
Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Depression; Female; Humans; Ontario; Paroxetine; Patient Compliance; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Treatment Outcome | 2016 |
Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression.
Topics: Aged; Cognitive Dysfunction; Depression; Female; Homes for the Aged; Humans; Male; Nursing Homes; Paroxetine; Risk; Selective Serotonin Reuptake Inhibitors | 2016 |
Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine.
Topics: Aged; Aged, 80 and over; Cohort Studies; Depression; Female; Follow-Up Studies; Homes for the Aged; Humans; Male; Medicare; Nursing Homes; Paroxetine; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk; Selective Serotonin Reuptake Inhibitors; United States | 2017 |
Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels - a review of routine practice.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Drug Interactions; Female; Humans; Middle Aged; Nortriptyline; Paroxetine | 2017 |
[Painful palate and xerostomia after using paroxetine].
Topics: Depression; Female; Humans; Middle Aged; Pain; Palate, Hard; Paroxetine; Selective Serotonin Reuptake Inhibitors; Xerophthalmia; Xerostomia | 2008 |
Expert opinion: migraine, psychiatric comorbidities, and treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Migraine Disorders; Paroxetine; Severity of Illness Index; Tryptamines | 2008 |
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Piperazines; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2008 |
Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Darkness; Depression; Disease Models, Animal; Gene Expression Regulation; Hippocampus; Light; Male; Mice; Mice, Inbred DBA; Oligonucleotide Array Sequence Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Swimming | 2008 |
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
Topics: Amino Acids; Amphetamine; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Operant; Darkness; Depression; Diazepam; Fever; Fluoxetine; Light; Male; Mice; Paroxetine; Receptors, Metabotropic Glutamate; Reinforcement Schedule; Stress, Psychological; Xanthenes | 2008 |
[Effects of paroxetine on protein kinase PKA, PKC and CaMKII activity in different brain regions in a rat depression model].
Topics: Animals; Brain; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP-Dependent Protein Kinases; Depression; Disease Models, Animal; Hippocampus; Male; Paroxetine; Protein Kinase C; Random Allocation; Rats | 2008 |
Strain differences in paroxetine-induced reduction of immobility time in the forced swimming test in mice: role of serotonin.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain Chemistry; Depression; Male; Melatonin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Motor Activity; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Species Specificity; Swimming; Tryptophan | 2008 |
The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects.
Topics: Animals; Antidepressive Agents; Aza Compounds; Behavior, Animal; Body Weight; Bridged Bicyclo Compounds, Heterocyclic; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Ejaculation; Exploratory Behavior; Male; Olfactory Bulb; Paroxetine; Rats; Rats, Sprague-Dawley; Reaction Time; Statistics, Nonparametric | 2008 |
Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Depression; Disease Models, Animal; Drug Synergism; Hippocampus; In Situ Hybridization; Male; Mice; Microdialysis; Microinjections; Motor Activity; Paroxetine; Receptor, trkB; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors | 2009 |
Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Hippocampus; Image Processing, Computer-Assisted; Male; Paroxetine; Proteins; Proteomics; Rats; Rats, Sprague-Dawley | 2010 |
Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Databases as Topic; Depression; Drug Costs; Drug Prescriptions; Drugs, Generic; Female; Fluoxetine; Humans; Insurance, Pharmaceutical Services; Likelihood Functions; Logistic Models; Male; Medication Adherence; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Time Factors; United States | 2009 |
Antidepressant-associated myoclonic status in a patient with symptomatic generalized epilepsy: does risk occur with therapeutic doses?
Topics: Antidepressive Agents; Depression; Duloxetine Hydrochloride; Electroencephalography; Epilepsy, Generalized; Humans; Male; Middle Aged; Paroxetine; Seizures; Thiophenes | 2009 |
The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Brain; Citalopram; Depression; Disease Models, Animal; Fenclonine; Fenfluramine; Fluorobenzenes; Freezing Reaction, Cataleptic; Male; Paroxetine; Piperidines; Protein Binding; Rats; Rats, Inbred Strains; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT4; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Swimming; Time Factors; Tritium | 2009 |
Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study.
Topics: Adult; Aged; Antidepressive Agents; Biomarkers; Citalopram; Depression; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors; Treatment Outcome | 2009 |
Persistent genital arousal disorder (PGAD): case report of long-term symptomatic management with electroconvulsive therapy.
Topics: Bipolar Disorder; Depression; Electroconvulsive Therapy; Female; Humans; Middle Aged; Orgasm; Paroxetine; Psychometrics; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Substance Withdrawal Syndrome; Time Factors | 2009 |
Paroxetine may cause increase in carcinoebmryonic antigen (CEA).
Topics: Carcinoembryonic Antigen; Depression; Humans; Male; Middle Aged; Paroxetine | 2009 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexanols; Depression; Depressive Disorder; Double-Blind Method; Drug Approval; Europe; Fluoxetine; Humans; Hypnotics and Sedatives; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptors, Melatonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Is the increase in LDL cholesterol induced by selective serotonin reuptake inhibitor therapy a blessing in disguise?
Topics: Affect; Anticholesteremic Agents; Cholesterol, LDL; Depression; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2010 |
Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Child; Child, Preschool; Depression; Humans; Infant; Paroxetine; Practice Patterns, Physicians'; United States; United States Food and Drug Administration; Young Adult | 2010 |
Effects of antidepressant treatment on N-acetyl aspartate and choline levels in the hippocampus and thalami of post-stroke depression patients: a study using (1)H magnetic resonance spectroscopy.
Topics: Aged; Analysis of Variance; Antidepressive Agents; Aspartic Acid; Brain Mapping; Case-Control Studies; Choline; Depression; Dose-Response Relationship, Drug; Female; Functional Laterality; Hippocampus; Humans; Magnetic Resonance Spectroscopy; Male; Paroxetine; Stroke; Thalamus; Tritium | 2010 |
Antidepressant-like pharmacological profile of 3-(4-fluorophenylselenyl)-2,5-diphenylselenophene: Involvement of serotonergic system.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Benzene Derivatives; Brain; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Freezing Reaction, Cataleptic; Hindlimb Suspension; Male; Mice; Monoamine Oxidase; Organoselenium Compounds; Paroxetine; Protein Binding; Serotonin; Serotonin Agents; Swimming; Synaptosomes; Time Factors; Tritium | 2010 |
ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression.
Topics: Aged; Aging; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Depression; Female; Genotype; Humans; Japan; Male; Paroxetine; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2010 |
A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Antidepressive Agents, Second-Generation; Blood Pressure; Cross-Sectional Studies; Depression; Female; Fluoxetine; Gene Frequency; Heart Rate; Homozygote; Humans; Linear Models; Male; Paroxetine; Pharmacogenetics; Phenotype; Pilot Projects; Receptors, Adrenergic, beta-1; Retrospective Studies; Risk Assessment; Risk Factors; Selective Serotonin Reuptake Inhibitors; Young Adult | 2010 |
Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence.
Topics: Abnormalities, Drug-Induced; Adult; Depression; Evidence-Based Medicine; Female; Heart Defects, Congenital; Humans; Meta-Analysis as Topic; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Selective Serotonin Reuptake Inhibitors; Uncertainty | 2010 |
Differences in clinical effect and tolerance between fluvoxamine and paroxetine: a switching study in patients with depression.
Topics: Adult; Depression; Depressive Disorder; Drug Substitution; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Treatment Outcome; Young Adult | 2010 |
Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior.
Topics: Amidohydrolases; Amygdala; Animals; Antidepressive Agents; Depression; Diet; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; Glutamate Dehydrogenase; Hypothalamus; Magnesium Deficiency; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Oxidative Stress; Paroxetine; Proteomics; Superoxide Dismutase; Tandem Mass Spectrometry; Voltage-Dependent Anion Channel 1 | 2011 |
[Paroxetine, hypothyroidism and, despite everything, inadequate antidiuretic hormone secretion].
Topics: Aged, 80 and over; Depression; Female; Humans; Hyponatremia; Hypothyroidism; Inappropriate ADH Syndrome; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thyroxine | 2011 |
Efficacy of prophylactic treatment with selective serotonin reuptake inhibitors for depression after open-heart surgery.
Topics: Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Cardiac Surgical Procedures; Case-Control Studies; Depression; Emergencies; Female; Heart Diseases; Humans; Middle Aged; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2011 |
BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response.
Topics: Aged; Alleles; Alzheimer Disease; Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Depression; Female; Genotype; Humans; Linkage Disequilibrium; Male; Paroxetine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Treatment of depression as part of end-of-life care.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Carcinoma, Squamous Cell; Depression; Drug Therapy, Combination; Esophageal Neoplasms; Fatal Outcome; Female; Humans; Mianserin; Mirtazapine; Paroxetine; Terminal Care | 2008 |
[Approximate entropy of the placebo effect in clinical trials of newer antidepressants].
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Placebo Effect; Placebos; Severity of Illness Index; Venlafaxine Hydrochloride | 2010 |
Sub-chronic dietary tryptophan depletion--an animal model of depression with improved face and good construct validity.
Topics: Aldosterone; Analysis of Variance; Animals; Body Weight; Brain; Calcium-Binding Proteins; Catecholamines; Chromatography, High Pressure Liquid; Corticosterone; Depression; Diet; Disease Models, Animal; DNA-Binding Proteins; Kynurenic Acid; Kynurenine; Male; Nerve Tissue Proteins; Nucleobindins; Paroxetine; Protein Binding; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Swimming; Time Factors; Tritium; Tryptophan | 2012 |
The declining use of reboxetine in years 2000 to 2006: a pharmacoepidemiological comparative study.
Topics: Antidepressive Agents; Depression; Fluoxetine; Humans; Morpholines; Paroxetine; Pharmacoepidemiology; Practice Patterns, Physicians'; Publication Bias; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2012 |
[Application of antidepressant to treat patients in the department of otolaryngology].
Topics: Antidepressive Agents, Second-Generation; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Tinnitus | 2012 |
Effects of diphenyl diselenide on depressive-like behavior in ovariectomized mice submitted to subchronic stress: involvement of the serotonergic system.
Topics: Animals; Antidepressive Agents; Benzene Derivatives; Cerebral Cortex; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Hippocampus; Immobility Response, Tonic; Menopause; Mice; Mice, Inbred Strains; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Ondansetron; Organoselenium Compounds; Ovariectomy; Pargyline; Paroxetine; Piperazines; Pyridines; Ritanserin; Serotonergic Neurons; Serotonin Antagonists; Stress, Psychological | 2012 |
[Efficacy of adepress (paroxetine) in the treatment of depression in patients with chronic cerebral ischemia in the late recovery phase of ischemic stroke with the estimation of the velocity of passive transmembrane ion transport].
Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Chronic Disease; Cognition; Depression; Erythrocyte Membrane; Female; Humans; Ion Transport; Lithium; Male; Middle Aged; Paroxetine; Sodium; Treatment Outcome | 2012 |
Paroxetine and neonatal withdrawal syndrome.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Infant, Newborn; Male; Neonatal Abstinence Syndrome; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects | 2010 |
Differences in FKBP51 regulation following chronic social defeat stress correlate with individual stress sensitivity: influence of paroxetine treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Male; Mice; Mice, Inbred C57BL; Paroxetine; Social Behavior; Stress, Psychological; Tacrolimus Binding Proteins; Treatment Outcome | 2012 |
Ask the doctor. I have been taking an SSRI (paroxetine HCI) for many years for chronic anxiety and, at times, panic attacks. What are the side effects of the long-term use of SSRIs?
Topics: Adult; Antidepressive Agents, Second-Generation; Child; Depression; Humans; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Suicide Prevention; Young Adult | 2012 |
Breast cancer and antidepressant use.
Topics: Adult; Aged; Antidepressive Agents; Anxiety; Breast Neoplasms; Contraindications; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Drug Interactions; Female; Hot Flashes; Humans; Paroxetine; Prodrugs; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen | 2012 |
Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Emotions; Mice; Olfactory Bulb; Ondansetron; Paroxetine; Photoperiod; Quinoxalines; Rats; Rats, Wistar; Reserpine; Serotonin 5-HT3 Receptor Antagonists; Swimming | 2012 |
Evidence for the involvement of 5-HT1A receptor in the acute antidepressant-like effect of creatine in mice.
Topics: Animals; Antidepressive Agents; Creatine; Depression; Depressive Disorder; Hindlimb Suspension; Humans; Mice; Paroxetine; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Antagonists | 2013 |
[Increased perioperative blood loss during treatment with paroxetine].
Topics: Antidepressive Agents, Second-Generation; Blood Loss, Surgical; Blood Platelet Disorders; Depression; Humans; Male; Middle Aged; Paroxetine; Platelet Aggregation; Selective Serotonin Reuptake Inhibitors | 2002 |
Reputations at stake.
Topics: Access to Information; Clinical Trials as Topic; Compensation and Redress; Consumer Product Safety; Depression; Disclosure; Drug Industry; Humans; Intellectual Property; Paroxetine; Publishing; United Kingdom; United States; Violence | 2002 |
Paroxetine-associated psoriasis.
Topics: Adult; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Psoriasis; Selective Serotonin Reuptake Inhibitors | 2002 |
A case of paroxetine-induced galactorrhea.
Topics: Adult; Antipsychotic Agents; Anxiety; Depression; Female; Galactorrhea; Humans; Paroxetine | 2002 |
[Neurobiology and genetics of anxiety in an animal model].
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Arginine Vasopressin; Arousal; Corticotropin-Releasing Hormone; Depression; Dexamethasone; Disease Models, Animal; Hypothalamo-Hypophyseal System; Motor Activity; Paroxetine; Phenotype; Pituitary-Adrenal System; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Rats; Rats, Inbred Strains; Receptors, Vasopressin | 2003 |
Implantation of a slow release corticosterone pellet induces long-term alterations in serotonergic neurochemistry in the rat brain.
Topics: Adrenal Glands; Animals; Body Weight; Carrier Proteins; Corticosterone; Depression; Disease Models, Animal; Drug Implants; Frontal Lobe; Hippocampus; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Organ Size; Paroxetine; Rats; Rats, Inbred Strains; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time | 2003 |
Determination of paroxetine in geriatric depression by high-performance liquid chromatography.
Topics: Age Factors; Aged; Analysis of Variance; Chromatography, High Pressure Liquid; Depression; Drug Interactions; Drug Monitoring; Female; Humans; Male; Paroxetine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity | 2003 |
British panel bans use of antidepressant to treat children.
Topics: Adolescent; Antidepressive Agents; Child; Depression; England; Humans; Legislation, Drug; Paroxetine; Suicide; United States; United States Food and Drug Administration | 2003 |
Are SSRIs safe for children?
Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Depression; Fatigue; Humans; Nausea; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders | 2003 |
Antidepressant-like effects in various mice strains in the tail suspension test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Bupropion; Citalopram; Depression; Desipramine; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Hindlimb Suspension; Imipramine; Male; Mice; Mice, Inbred Strains; Paroxetine; Selective Serotonin Reuptake Inhibitors; Species Specificity | 2003 |
Early Alzheimer's disease.
Topics: Dementia; Depression; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2004 |
Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.
Topics: Aged; Aged, 80 and over; Depression; Diuretics; Female; Humans; Hydrochlorothiazide; Hypertension; Hyponatremia; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sodium Chloride Symporter Inhibitors | 2004 |
Drug company experts advised staff to withhold data about SSRI use in children.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Child Welfare; Clinical Trials as Topic; Data Interpretation, Statistical; Depression; Drug Industry; Humans; North America; Paroxetine; Selective Serotonin Reuptake Inhibitors; Workforce | 2004 |
[Case of prolonged recovery from serotonin syndrome caused by paroxetine].
Topics: Amoxapine; Cytochrome P-450 CYP2D6; Depression; Diagnosis, Differential; Drug Interactions; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Serotonin Syndrome; Time Factors | 2003 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Droxidopa; Fluoxetine; Gene Deletion; Mice; Morpholines; Norepinephrine; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Tail | 2004 |
[Combination of serotonergic agents resulted in severe adverse effects].
Topics: Antidepressive Agents, Second-Generation; Buspirone; Cytochrome P-450 CYP2D6; Depression; Drug Interactions; Drug Therapy, Combination; Female; Humans; Middle Aged; Papaverine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Serotonin Syndrome; Vasodilator Agents | 2004 |
Spitzer sues drug giant for deceiving doctors.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Consumer Advocacy; Contraindications; Depression; Drug Industry; Fraud; Humans; Paroxetine; Physicians; Truth Disclosure; United Kingdom; United States; United States Food and Drug Administration | 2004 |
Neonatal complications after intrauterine exposure to SSRI antidepressants.
Topics: Antidepressive Agents; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; France; Humans; Infant, Newborn; Neonatal Abstinence Syndrome; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Risk; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Paroxetine, a selective serotonin reuptake inhibitor, reduces depressive symptoms and subjective handicaps in patients with dizziness.
Topics: Activities of Daily Living; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Depression; Dizziness; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2004 |
A question of balance.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Clinical Trials as Topic; Depression; Drug Industry; Humans; Licensure; Paroxetine; Patient Advocacy; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Truth Disclosure; United Kingdom | 2004 |
Prevalence of induced mania in patients treated with milnacipran: a comparison with paroxetine.
Topics: Adult; Aged; Bipolar Disorder; Cohort Studies; Cyclopropanes; Depression; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Prevalence; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2004 |
[Unfortunate title?].
Topics: Adolescent; Child; Depression; Fluoxetine; Humans; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work | 2004 |
Selective serotonin reuptake inhibitors in familial Mediterranean fever: are we treating depression or inflammation?
Topics: Adult; Antidepressive Agents, Second-Generation; Arthritis; Colchicine; Depression; Drug Therapy, Combination; Familial Mediterranean Fever; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2005 |
Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
Topics: Cohort Studies; Cyclopropanes; Depression; Drug Administration Schedule; Fluvoxamine; Humans; Milnacipran; Paroxetine; Psychomotor Agitation; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2004 |
Chronoamperometry to determine differential reductions in uptake in brain synaptosomes from serotonin transporter knockout mice.
Topics: Animals; Brain; Depression; Kinetics; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Knockout; Microelectrodes; Nerve Tissue Proteins; Neurotransmitter Agents; Oxygen; Paroxetine; Potentiometry; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stress, Psychological; Synaptosomes | 2005 |
Hyponatremia upon resumption of paroxetine therapy.
Topics: Aged; Depression; Female; Follow-Up Studies; Humans; Hyponatremia; Infusions, Intravenous; Isotonic Solutions; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sodium; Sodium Chloride | 2005 |
Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
Topics: Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Citalopram; Cyclohexanols; Depression; Female; Fluoxetine; Humans; Male; Paroxetine; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Venlafaxine Hydrochloride | 2005 |
Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Anxiety Disorders; Citalopram; Cohort Studies; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Patient Compliance; Patient Dropouts; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic | 2005 |
Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.
Topics: Adult; Citalopram; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Netherlands; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Surveys and Questionnaires; Time Factors | 2005 |
[St. John's wort in depression. The question is not whether it is effective but how do we use it].
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depression; Humans; Hypericum; Meta-Analysis as Topic; Paroxetine; Phytotherapy; Placebos; Selective Serotonin Reuptake Inhibitors | 2005 |
Antidepressants and suicide: a commentary on a significant contribution to this debate.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Child; Depression; Dothiepin; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide, Attempted; Time Factors; United Kingdom | 2005 |
Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats.
Topics: Alkynes; Animals; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Benzoxazines; Cyclopropanes; Cytokines; Depression; Enzyme-Linked Immunosorbent Assay; Interleukin-1; Male; Maze Learning; Oxazines; Paroxetine; Rats; Rats, Wistar; Stress, Psychological; Tumor Necrosis Factor-alpha | 2005 |
Paroxetine-associated spontaneous sexual stimulation.
Topics: Depression; Female; Humans; Libido; Middle Aged; Orgasm; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological | 2005 |
A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol.
Topics: Algorithms; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Models, Theoretical; Nonlinear Dynamics; Paroxetine; Pindolol; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Time Factors; Treatment Outcome | 2005 |
Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels.
Topics: Animals; Antidepressive Agents; Biopterins; Brain; Chlorocebus aethiops; COS Cells; Depression; Enzyme Induction; Freezing Reaction, Cataleptic; Gene Expression Regulation, Developmental; Humans; Imipramine; Mice; Mice, Inbred Strains; Paroxetine; Raphe Nuclei; Recombinant Fusion Proteins; RNA, Messenger; Serotonin; Tryptophan; Tryptophan Hydroxylase | 2006 |
Comparison of first refill rates among users of sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Anxiety Disorders; Citalopram; Cohort Studies; Cost Sharing; Databases, Factual; Depression; Drug Prescriptions; Female; Humans; Logistic Models; Male; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2006 |
Planning and analysis of three-arm non-inferiority trials with binary endpoints.
Topics: Controlled Clinical Trials as Topic; Data Interpretation, Statistical; Depression; Duloxetine Hydrochloride; Humans; Paroxetine; Research Design; Sample Size; Selective Serotonin Reuptake Inhibitors; Statistics as Topic; Therapeutic Equivalency; Thiophenes | 2007 |
Non-parametric estimation for baseline hazards function and covariate effects with time-dependent covariates.
Topics: Algorithms; Angiogenesis Inhibitors; Computer Simulation; Data Interpretation, Statistical; Depression; Humans; Interferon-alpha; Melanoma; Models, Statistical; Paroxetine; Patient Dropouts; Statistics, Nonparametric | 2007 |
Reduced platelet [3H]paroxetine binding in anorexia nervosa: relationship to eating symptoms and personality pathology.
Topics: Adolescent; Adult; Anorexia Nervosa; Anxiety; Blood Platelets; Body Mass Index; Bulimia; Depression; Diet, Reducing; Feeding Behavior; Female; Humans; Paroxetine; Personality Disorders; Personality Inventory; Psychometrics; Radioligand Assay; Serotonin Plasma Membrane Transport Proteins; Tritium | 2006 |
Ear dyskinesia.
Topics: Botulinum Toxins, Type A; Depression; Dyskinesias; Ear; Electromyography; Female; Humans; Middle Aged; Muscle Contraction; Neuromuscular Agents; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2006 |
Effect of antidepressant drugs on 6-OHDA-treated mice in the FST.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biogenic Monoamines; Cerebral Cortex; Citalopram; Depression; Desipramine; Dopamine Uptake Inhibitors; Hippocampus; Hypothalamus; Imipramine; Injections, Intraventricular; Male; Mice; Neostriatum; Oxidopamine; Paroxetine; Swimming | 2007 |
Usefulness of paroxetine in depressed men with paroxysmal atrial fibrillation.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Depression; Drug Therapy, Combination; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2006 |
[Treatment of non-psychotic depression in outpatient clinic].
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outpatients; Paroxetine; Treatment Outcome | 2006 |
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.
Topics: Adult; Antidepressive Agents; Chi-Square Distribution; Depression; Dose-Response Relationship, Drug; Female; Fluvoxamine; Humans; Japan; Male; Middle Aged; Paroxetine; Receptors, Serotonin, 5-HT2; Retrospective Studies; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index | 2006 |
Alopecia areata with comorbid depression: early resolution with combined paroxetine-triamcinolone treatment.
Topics: Adult; Alopecia Areata; Antidepressive Agents, Second-Generation; Depression; Drug Therapy, Combination; Female; Humans; Paroxetine; Triamcinolone | 2006 |
Night sweats and elevated follicle-stimulating hormone levels while taking selective serotonin reuptake inhibitors.
Topics: Adult; Depression; Female; Fluoxetine; Follicle Stimulating Hormone; Humans; Infertility, Female; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sweating | 2006 |
Statistical analysis of longitudinal psychiatric data with dropouts.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depression; Humans; Likelihood Functions; Longitudinal Studies; Mental Disorders; Nortriptyline; Paroxetine; Patient Dropouts; Randomized Controlled Trials as Topic; Regression Analysis | 2007 |
Resolving the onset of antidepressants' clinical actions: critical for clinical practice and new drug development.
Topics: Affect; Animals; Antidepressive Agents; Clinical Trials as Topic; Depression; Desipramine; Drug Design; Hostility; Humans; Motor Activity; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome | 2006 |
[A case of Parkinson's disease with neuroleptic malignant syndrome induced by paroxetine].
Topics: Aged; Depression; Female; Humans; Neuroleptic Malignant Syndrome; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2006 |
Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depression; Drug Synergism; Female; Humans; Indoles; Isoindoles; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Thiazoles | 2007 |
SSRI antidepressants and birth defects.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Denmark; Depression; Female; Heart Defects, Congenital; Humans; Infant, Newborn; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; Selective Serotonin Reuptake Inhibitors; Sweden; Teratogens; United States | 2006 |
[A comparative study of efficacy and tolerability of antidepressants from different classes in mild and moderate depression].
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Depression; Drug Tolerance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Severity of Illness Index; Thiazepines; Treatment Outcome | 2006 |
Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever.
Topics: Acute-Phase Reaction; Adolescent; Adult; Blood Sedimentation; C-Reactive Protein; Colchicine; Depression; Drug Therapy, Combination; Familial Mediterranean Fever; Female; Fibrinogen; Fibromyalgia; Fluoxetine; Humans; Leukocyte Count; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Altered brain activation pattern associated with drug-induced attenuation of enhanced depression-like behavior in rats bred for high anxiety.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Anxiety; Brain; Depression; Immobility Response, Tonic; Male; Paroxetine; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Statistics, Nonparametric; Stress, Psychological | 2007 |
[Case report of an elderly woman who developed a pain disorder following her husband's death].
Topics: Aged; Antidepressive Agents, Second-Generation; Death; Depression; Female; Genitalia, Female; Humans; Life Change Events; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Spouses; Treatment Outcome | 2006 |
Determination of paroxetine in human saliva by reversed-phase high-performance liquid chromatography with UV detection.
Topics: Antidepressive Agents, Second-Generation; Biomarkers; Chromatography, High Pressure Liquid; Depression; Drug Monitoring; Humans; Paroxetine; Patient Compliance; Saliva | 2007 |
Neonatal convulsions secondary to paroxetine withdrawal.
Topics: Antidepressive Agents, Second-Generation; Depression; Diagnosis, Differential; Epilepsy, Benign Neonatal; Female; Humans; Infant, Newborn; Male; Maternal Exposure; Neonatal Abstinence Syndrome; Paroxetine; Pregnancy; Pregnancy Complications | 2007 |
Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Body Weight; Depression; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Food Preferences; Glucocorticoids; Male; Paroxetine; Rats; Rats, Wistar; Stress, Psychological; Time Factors | 2007 |
Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Topics: Aged; Aged, 80 and over; Algorithms; Bayes Theorem; Citalopram; Cost-Benefit Analysis; Depression; Drugs, Generic; Female; Fluoxetine; Humans; Male; Medicare; Models, Statistical; Paroxetine; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; United States | 2007 |
Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy.
Topics: Antidepressive Agents; Depression; Humans; Paroxetine; Polymorphism, Genetic; Receptor, Serotonin, 5-HT2A; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome | 2009 |
[Paroxetine-induced hyponatremia in an elderly man due to the syndrome of inappropriate secretion of antidiuretic hormone].
Topics: Aged, 80 and over; Depression; Diagnosis, Differential; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2008 |
Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Depression; Drinking; Escape Reaction; Exploratory Behavior; Fear; Helplessness, Learned; Injections, Intraperitoneal; Long-Term Care; Male; Mental Recall; Mice; Motivation; Motor Activity; Paroxetine; Pattern Recognition, Visual; Recognition, Psychology; Stress, Psychological; Sucrose; Taste | 2008 |
[Fluoxetine in perspective].
Topics: Amitriptyline; Depression; Double-Blind Method; Fluoxetine; Humans; Paroxetine | 1994 |
Parkinsonism exacerbated by paroxetine.
Topics: Adult; Depression; Female; Humans; Parkinson Disease; Paroxetine | 1994 |
New drugs. In the realm of the brain.
Topics: Central Nervous System Agents; Depression; Humans; Hypnotics and Sedatives; Migraine Disorders; Paroxetine; Pyridines; Sleep Initiation and Maintenance Disorders; Sumatriptan; Zolpidem | 1993 |
Paroxetine: a new selective serotonin uptake inhibitor for depression.
Topics: Depression; Humans; Paroxetine | 1993 |
Incentive bias?
Topics: 1-Naphthylamine; Clinical Trials as Topic; Depression; Drug Administration Schedule; Drug Costs; Drug Industry; Financial Support; Humans; Paroxetine; Prejudice; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Hyperglycemia associated with paroxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Humans; Hyperglycemia; Paroxetine | 1996 |
SIADH caused by paroxetine.
Topics: Aged; Depression; Humans; Inappropriate ADH Syndrome; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1996 |
Protective effect of citalopram against the attenuation of the alpha 1-potentiation of cAMP formation in Fischer 344 strain rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Body Weight; Brain Chemistry; Citalopram; Cyclic AMP; Depression; Imipramine; Male; Motor Activity; Nerve Tissue Proteins; Paroxetine; Radioligand Assay; Rats; Rats, Inbred F344; Receptors, Adrenergic, alpha-1; Selective Serotonin Reuptake Inhibitors; Stress, Psychological | 1997 |
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Topics: 1-Naphthylamine; Aggression; Animals; Anxiety; Binding, Competitive; Citalopram; Depression; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Rats; Rats, Wistar; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sertraline; Vocalization, Animal | 1997 |
[The concept of therapeutic use of Paroxetin proves to be successful in clinical practice].
Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder; Geriatric Psychiatry; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1995 |
Efficacy of paroxetine for the treatment of depression in the context of HIV infection.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; HIV Infections; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales | 1997 |
Paroxetine-induced mania.
Topics: Adolescent; Antidepressive Agents; Bipolar Disorder; Depression; Humans; Lithium Carbonate; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1997 |
High affinity [3H]imipramine and [3H]paroxetine binding sites in suicide brains.
Topics: Adolescent; Adult; Aged; Binding Sites; Brain; Depression; Female; Humans; Imipramine; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Suicide | 1997 |
Individual differences in response to imipramine in the mouse tail suspension test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Desipramine; Disease Models, Animal; Imipramine; Individuality; Male; Mice; Mice, Inbred Strains; Motor Activity; Paroxetine; Restraint, Physical | 1997 |
Serotonin syndrome in a prisoner.
Topics: Antidepressive Agents, Second-Generation; Ataxia; Confusion; Depression; Drug Interactions; Forensic Psychiatry; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Prisoners; Psychotropic Drugs; Risk Factors; Selective Serotonin Reuptake Inhibitors; Syndrome | 1998 |
SSRI supplementation of antimanic medication in dysphoric mania.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depression; Drug Therapy, Combination; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1998 |
Spontaneous ecchymoses due to paroxetine administration.
Topics: Antidepressive Agents, Second-Generation; Depression; Ecchymosis; Female; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1998 |
[Depression and Down syndrome].
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depression; Down Syndrome; Female; Humans; Paroxetine | 1998 |
Serotonin syndrome following the administration of tramadol with paroxetine.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Autonomic Nervous System Diseases; Central Nervous System Diseases; Depression; Drug Interactions; Female; Humans; Pain; Paroxetine; Selective Serotonin Reuptake Inhibitors; Syndrome; Tramadol | 1998 |
Depressive symptomatology during clozapine treatment: two case reports.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clomipramine; Clozapine; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Schizophrenia | 1998 |
Combining pindolol and paroxetine in an animal model of chronic antidepressant action--can early onset of action be detected?
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic beta-Antagonists; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Therapy, Combination; Exploratory Behavior; Hypothermia; Male; Olfactory Bulb; Paroxetine; Pindolol; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists | 1998 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Exercise Test; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 1998 |
Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine.
Topics: Adrenergic Uptake Inhibitors; Animals; Cyclohexanols; Depression; Desipramine; Hippocampus; Injections, Intravenous; Iontophoresis; Male; Norepinephrine; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 1998 |
Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings.
Topics: 1-Naphthylamine; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Drug Costs; Drug Utilization Review; Fluoxetine; Humans; Managed Care Programs; Models, Organizational; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; United States | 1995 |
Pharmacoeconomic issues in the treatment of depression.
Topics: Algorithms; Antidepressive Agents; Cost of Illness; Cost-Benefit Analysis; Depression; Drug Costs; Humans; Imipramine; Models, Economic; Paroxetine; United States | 1995 |
Treatment of vocally disruptive behaviour of multifactorial aetiology.
Topics: Aged; Akathisia, Drug-Induced; Behavior Therapy; Dementia; Depression; Female; Homes for the Aged; Humans; Mental Disorders; Noise; Nursing Homes; Paroxetine; Patient Compliance; Physical Therapy Modalities; Psychomotor Agitation; Restraint, Physical; Risperidone; Verbal Behavior | 1999 |
Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Drug Synergism; Exploratory Behavior; Hypothermia; Male; Motor Activity; Olfactory Bulb; Paroxetine; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists | 1999 |
Paroxetine and its uses in psychiatry.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Depression; Drug Interactions; Humans; Mental Disorders; Obsessive-Compulsive Disorder; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders | 1999 |
Behavioral changes in developing mice after prenatal exposure to paroxetine (Paxil)
Topics: Aggression; Animals; Animals, Newborn; Anxiety; Behavior, Animal; Body Weight; Depression; Exploratory Behavior; Female; Homing Behavior; Litter Size; Male; Maternal Exposure; Mice; Motor Activity; Paroxetine; Play and Playthings; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Selective Serotonin Reuptake Inhibitors; Sleep; Time Factors; Vocalization, Animal | 1999 |
An 87-year-old woman taking a benzodiazepine, 1 year later.
Topics: Aged; Aged, 80 and over; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Depression; Drug Therapy, Combination; Female; Humans; Paroxetine; Risk | 1999 |
Venlafaxine and paroxetine in treatment-resistant depression.
Topics: Cyclohexanols; Depression; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
[Withdrawal syndrome after the use of serotonin reuptake inhibitors].
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder; Female; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2000 |
[Tourette's syndrome and antidepressant therapy: exacerbation of nervous tics with paroxetine].
Topics: Antidepressive Agents, Tricyclic; Child; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluvoxamine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tics; Tourette Syndrome; Treatment Outcome; Trimipramine | 2000 |
The clinical response to total sleep deprivation and recovery sleep in geriatric depression: potential indicators of antidepressant treatment outcome.
Topics: Aged; Aging; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depression; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Deprivation; Treatment Outcome | 2000 |
Treatment of mild depression in elderly patients.
Topics: Aged; Antidepressive Agents, Second-Generation; Dementia; Depression; Dysthymic Disorder; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2000 |
Treatment of mild depression in elderly patients.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Dysthymic Disorder; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2000 |
By the way, doctor. I've been taking Paxil for depression for about six months. Although it's helped my symptoms of depression, I've lost interest in sex. Aside from stopping the medication, is there any way to regain my sexual function?
Topics: Antidepressive Agents, Second-Generation; Depression; Female; Humans; Libido; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
Dopaminergic sensitivity and prediction of antidepressant response.
Topics: Antidepressive Agents, Second-Generation; Apomorphine; Depression; Dopamine Agonists; Human Growth Hormone; Humans; Paroxetine; Predictive Value of Tests | 2000 |
Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study.
Topics: Adult; Depression; Female; Fluorine Radioisotopes; Humans; Male; Paroxetine; Prefrontal Cortex; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Spiperone; Tomography, Emission-Computed; Treatment Outcome | 2001 |
Disinhibition of libido: an adverse effect of SSRI?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Citalopram; Depression; Female; Humans; Libido; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Switzerland | 2001 |
Salmon calcitonin potentiates the analgesia induced by antidepressants.
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Brain Chemistry; Calcitonin; Depression; Dose-Response Relationship, Drug; Drug Synergism; Hydroxyindoleacetic Acid; Male; Mice; Nortriptyline; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Swimming | 2001 |
No correlation between aggression and platelet (3)H-paroxetine binding in obsessive-compulsive disorder patients.
Topics: Adolescent; Adult; Aggression; Carrier Proteins; Child; Depression; Female; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sex Factors | 2001 |
Prefrontal changes and treatment response prediction in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Prefrontal Cortex; Sertraline; Venlafaxine Hydrochloride | 2001 |
Cancer fatigue: one drug fails but more are in the pipeline.
Topics: Clinical Trials as Topic; Depression; Dexamethasone; Fatigue; Humans; Neoplasms; Paroxetine; Prednisolone; Selective Serotonin Reuptake Inhibitors; Treatment Failure | 2001 |
Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depression; Desipramine; Dopamine; Extracellular Space; Male; Microdialysis; Nucleus Accumbens; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Swimming | 2001 |
Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study.
Topics: Activities of Daily Living; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Case-Control Studies; Depression; Disabled Persons; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Activity; Paroxetine; Recovery of Function; Stroke; Stroke Rehabilitation | 2001 |
Drugs or psychotherapy for the elderly?
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Humans; Paroxetine; Psychotherapy | 2001 |
[Clinical characteristics and psychotropic therapy of depressive and anxious symptoms of patients with somatic diseases].
Topics: Adolescent; Adult; Anxiety; Depression; Female; Hospitals, General; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychophysiologic Disorders; Selective Serotonin Reuptake Inhibitors | 1999 |
[Paroxetine (paxil): use in clinical practice].
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Depression; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Cross-sensitivity between paroxetine and sertraline.
Topics: Adult; Depression; Drug Eruptions; Exanthema; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Treatment of psychotic depression associated with steroid therapy in Churg-Strauss syndrome.
Topics: Adrenal Cortex Hormones; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Churg-Strauss Syndrome; Cyclohexanols; Depression; Electroconvulsive Therapy; Female; Humans; Middle Aged; Paroxetine; Risperidone; Venlafaxine Hydrochloride | 2002 |
SSRIs: take your pick.
Topics: Depression; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Modulation of [3H]paroxetine binding to the 5-hydroxytryptamine uptake site in an animal model of depression.
Topics: Animals; Binding Sites; Depression; Male; Paroxetine; Piperidines; Rats; Receptors, Serotonin; Reference Values; Serotonin Antagonists; Tritium | 1991 |